register_number stringlengths 11 11 | secondary_id listlengths 1 10 | url stringlengths 44 44 | brief_title stringlengths 20 290 | brief_summary stringlengths 63 5.05k | official_title stringlengths 25 483 ⌀ | intervention listlengths 1 19 | arm_intervention listlengths 1 21 ⌀ | f_condition listlengths 1 135 | sponsor listlengths 1 1 | collaborator listlengths 1 25 | experimental_drug listlengths 1 13 | study_identifier listlengths 1 7 ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT05890963 | [
{
"id_field": "org_study_id",
"id_value": [
"AAAU5207"
]
},
{
"id_domain": "U.S. Military HIV Research Program (MHRP)",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"W81XWH-18-2-0040"
]
},
{
"id_domain": "WRAIR IRB",
"... | https://clinicaltrials.gov/study/NCT05890963 | 10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults | This is an open-label phase 1b clinical trial enrolling people living with HIV (PLWH) who are antiretroviral therapy (ART)-naïve or have not been on ART for > 24 weeks. This study will enroll PLWH to assess the safety, tolerability, and antiviral effect of bispecific and long-acting bNAbs, alone and in combination. The... | Phase 1b Single Dose Clinical Trial of a Novel Long-Acting Bispecific Antibody in People With HIV to Inform Development for HIV Pre- and Post-Exposure Prophylaxis | [
{
"description": "ART is a combination of three or more drugs from different classes of antiretroviral medication.",
"name": "ART",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"antiretroviral therapy"
],
"type": "Drug"
},
{
"description": "10E8.4/iMab... | [
{
"design_group_description": "Participants will receive standard daily oral ART.",
"design_group_title": "Arm 1: Oral ART",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_descriptio... | [
"HIV-1-infection"
] | [
"Columbia University"
] | [
"The Henry M. Jackson Foundation"
] | [
[
{
"name": "艾巴利珠单抗",
"lang": "CN"
},
{
"name": "Ibalizumab-UIYK",
"lang": "EN"
}
],
[
{
"name": "VRC-07-523",
"lang": "EN"
}
]
] | null |
NCT03768310 | [
{
"id_field": "org_study_id",
"id_value": [
"H-36578 CARMA"
]
}
] | https://clinicaltrials.gov/study/NCT03768310 | CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) | This study is for patients that are having a bone marrow or stem cell transplant for either a type of cancer of the blood called Leukemia or a cancer of the lymph nodes called Non-Hodgkin's Lymphoma (NHL). Although a transplant can cure leukemia or lymphoma, some people will relapse (return of the disease). In those wh... | Phase I Study of the Administration of CD19 Chimeric Antigen Receptor Multivirus-Specific Cytotoxic T Lymphocytes for Prophylaxis or Therapy of Relapse of CD19 Positive Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation | [
{
"description": "Patients will be evaluated in the clinic and a single dose of CD19.CAR-multiVSTs will be given by intravenous injection on or after 30 days of the transplant (between days 30 and 90). A time period of 6 weeks will constitute the time for clinical safety monitoring.",
"name": "CD19.CAR-mult... | [
{
"design_group_description": "Group A: Patients with no evidence of disease after having a bone marrow transplant.<br/>T cells will be given at the specified dose on or after day 30 after the bone marrow transplant. Three dose levels will be studied in both groups of patients (Group A and Group B). The lowest ... | [
"Non-hodgkin Lymphoma",
"Acute Lymphoblastic Leukemia"
] | [
"Baylor College of Medicine"
] | [
"Center For Cell & Gene Therapy",
"The Methodist Hospital Research Institute"
] | [
[
{
"name": "Virus-specific-CD19.CAR(Baylor College of Medicine)",
"lang": "EN"
}
]
] | null |
NCT03820180 | [
{
"id_field": "org_study_id",
"id_value": [
"BECRO/RESP/BREATH-PK250"
]
}
] | https://clinicaltrials.gov/study/NCT03820180 | A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers | Bioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder | A Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Study Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Hea... | [
{
"description": "2 inhalations of Test and Reference product in each study period",
"name": "Test Product",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals"
],
"type": "Dru... | [
{
"design_group_description": "Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals",
"design_group_title": "Test Product",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Bioequivalence"
] | [
"Respirent Pharmaceuticals Co. Ltd."
] | [
"Becro Ltd."
] | [
[
{
"name": "富马酸二甲酯",
"lang": "CN"
},
{
"name": "Dimethyl fumarate",
"lang": "EN"
},
{
"name": "フマル酸ジメチル",
"lang": "JP"
}
]
] | null |
NCT03347292 | [
{
"id_field": "org_study_id",
"id_value": [
"19497"
]
},
{
"id_domain": "Merck Sharp & Dohme",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"KN-743"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value":... | https://clinicaltrials.gov/study/NCT03347292 | Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC | This study will determine if the combination of regorafenib and pembrolizumab is safe and tolerated in patients with advanced liver cancer. In addition, the study will explore the anti-tumor activity of this combination as well as potentially identifying blood and tissue biomarkers associated with disease activity, sta... | A Multicenter, Non-randomized, Open-label Dose Escalation Phase Ib Study of Regorafenib in Combination With Pembrolizumab in Patients With Advanced Hepatocellular Carcinoma (HCC) With no Prior Systemic Therapy | [
{
"description": "Regorafenib 80mg/120mg/160mg q.d., 3 weeks on / 1 week off + pembrolizumab 200mg i.v. every 3 weeks",
"name": "Regorafenib(Stivarga, BAY73-4506)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "200 mg i.v.(Intravenous(ly)) every 3... | [
{
"design_group_description": "The regorafenib starting dose will be 120 mg q.d.(once daily) 3 weeks on / 1 week off in combination with the recommended dose of pembrolizumab (200 mg Q3W). Pembrolizumab dose will not be escalated or de-escalated.",
"design_group_title": "Dose escalation",
"design_group_... | [
"Carcinoma, Hepatocellular"
] | [
"Bayer AG"
] | [
"Merck Sharp & Dohme Corp."
] | [
[
{
"name": "瑞戈非尼",
"lang": "CN"
},
{
"name": "Regorafenib",
"lang": "EN"
},
{
"name": "レゴラフェニブ水和物",
"lang": "JP"
}
],
[
{
"name": "帕博利珠单抗",
"lang": "CN"
},
{
"name": "Pembrolizumab",
"lang": "EN"
},
{
... | null |
NCT04691817 | [
{
"id_field": "org_study_id",
"id_value": [
"UPCC 16520"
]
},
{
"id_field": "secondary_id",
"id_value": [
"UPCC 16520"
]
}
] | https://clinicaltrials.gov/study/NCT04691817 | Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy | This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer. | A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy | [
{
"description": "1200mg infusion",
"name": "Atezolizumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Tecentriq"
],
"type": "Drug"
},
{
"description": "Tocilizumab 6mg/kg or 4mg/kg infusion",
"name": "Tocilizumab",
"normalized_type": "3d1aa... | [
{
"design_group_description": "Participants receive Atezolizumab 1200mg IV and Tocilizumab 6mg/kg IV (or Tocilizumab 4mg/kg IV) every 21 days",
"design_group_title": "Atezolizumab and Tocilizumab",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c... | [
"Lung Cancer, Nonsmall Cell"
] | [
"Abramson Cancer Center"
] | [
"Genentech, Inc."
] | [
[
{
"name": "托珠单抗",
"lang": "CN"
},
{
"name": "Tocilizumab",
"lang": "EN"
},
{
"name": "トシリズマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "阿替利珠单抗",
"lang": "CN"
},
{
"name": "Atezolizumab",
"lang": "EN"
},
{
... | null |
NCT02012296 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB13-0979"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2013-02151"
]
},
{
"id_field": "secondary_id",
"id_valu... | https://clinicaltrials.gov/study/NCT02012296 | Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer | This partially randomized phase I/II trial studies the side effects and best dose of enzalutamide and mifepristone when given together and to see how well they work in treating patients with metastatic hormone resistant prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such ... | A Phase I/II Trial of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Mifepristone for Patients With Metastatic Castration Resistant Prostate Cancer (CRPC) | [
{
"description": "Given PO",
"name": "enzalutamide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"MDV3100",
"XTANDI",
"selective androgen receptor modulator MDV3100"
],
"type": "Drug"
},
{
"description": "Given PO",
"name": "mifepristo... | [
{
"design_group_description": "Patients receive enzalutamide PO per standard of care.",
"design_group_title": "Treatment (enzalutamide)",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"interventi... | [
"Hormone-resistant Prostate Cancer",
"Recurrent Prostate Cancer",
"Stage IV Prostate Cancer"
] | [
"The University of Chicago"
] | [
"National Cancer Institute"
] | [
[
{
"name": "恩扎卢胺",
"lang": "CN"
},
{
"name": "Enzalutamide",
"lang": "EN"
},
{
"name": "エンザルタミド",
"lang": "JP"
}
],
[
{
"name": "米非司酮",
"lang": "CN"
},
{
"name": "Mifepristone",
"lang": "EN"
},
{
"name... | null |
NCT03023423 | [
{
"id_field": "org_study_id",
"id_value": [
"CR108256"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2016-002579-83"
]
},
{
"id_domain": "Janssen Research & Development, LLC",
"id_field": "secondary_id",
"id_type": "Other I... | https://clinicaltrials.gov/study/NCT03023423 | A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer | The purpose of the study is to compare the overall response rate (ORR) in non-small cell lung cancer (NSCLC) participants treated with daratumumab in combination with atezolizumab versus atezolizumab alone. | A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination With Atezolizumab Compared With Atezolizumab Alone in Subjects With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer | [
{
"description": "Participants will receive atezolizumab 1200 mg intravenously.",
"name": "Atezolizumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Participants will receive daratumumab 16 mg/kg intravenously.",
"name": "Daratumumab",
... | [
{
"design_group_description": "Participants in Treatment Arm A will receive Atezolizumab 1,200 milligram (mg) intravenously (IV) on Day 1 of every 21-day cycle. Participants with confirmed disease progression based on RECIST 1.1 may cross over to Arm B and receive daratumumab and atezolizumab, provided crossove... | [
"Carcinoma, Non-Small-Cell Lung"
] | [
"Janssen Research & Development LLC"
] | [
"Genentech, Inc."
] | [
[
{
"name": "达雷妥尤单抗",
"lang": "CN"
},
{
"name": "Daratumumab",
"lang": "EN"
},
{
"name": "ダラツムマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "阿替利珠单抗",
"lang": "CN"
},
{
"name": "Atezolizumab",
"lang": "EN"
},
{
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "88222433530e23ee2858d84225e32888",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "DARZALEX"
}
] |
NCT03252756 | [
{
"id_field": "org_study_id",
"id_value": [
"17-01001"
]
}
] | https://clinicaltrials.gov/study/NCT03252756 | Effects of Cannabidiol in Alcohol Use Disorder | The goal of the proposed project is to begin rigorous study of the clinically relevant effects of non-psychoactive phytocannabinoid cannabidiol (CBD) in patients with severe alcohol use disorder (AUD). This double-blind, randomized proof-of-concept study (n = 40) is designed to assess feasibility and contrast effects o... | Effects of Cannabidiol in Alcohol Use Disorder | [
{
"description": "Saline taken by mouth (PO)",
"name": "Placebo",
"normalized_type": "ffd65a2d86954c7285f258adfa9c2916",
"type": "Other"
},
{
"description": "CBD taken by mouth (PO)",
"name": "Phytocannabinoid cannabidiol (CBD)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",... | [
{
"design_group_description": "600mg/day Saline taken by mouth (PO) for 4 weeks, immediately followed by 1200mg saline/ day (PO) for an additional 4 weeks (8 total weeks).",
"design_group_title": "Placebo for 4 weeks, followed by phytocannabinoid cannabidiol (CBD) for 4 weeks",
"design_group_type": "Exp... | [
"Alcohol Use Disorder"
] | [
"NYU Langone Health"
] | [
"Tilray Brands, Inc.",
"National Institutes of Health"
] | [
[
{
"name": "大麻二酚",
"lang": "CN"
},
{
"name": "Cannabidiol",
"lang": "EN"
}
]
] | null |
NCT03278782 | [
{
"id_field": "org_study_id",
"id_value": [
"2017-0272"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2018-01051"
]
},
{
"id_domain": "M D Anderson Cancer Center"... | https://clinicaltrials.gov/study/NCT03278782 | Study of Pembrolizumab (MK-3475) in Combination With Romidepsin | This phase I/II trial studies the side effects of pembrolizumab and romidepsin and to see how well they work in treating participants with peripheral T-cell lymphoma that has come back or that does not respond to treatment. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune syst... | A Phase I/II Study of Pembrolizumab (MK-3475) in Combination With Romidepsin in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma | [
{
"description": "Given IV",
"name": "Pembrolizumab",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Keytruda",
"Lambrolizumab",
"MK-3475",
"SCH 900475"
],
"type": "Biological"
},
{
"description": "Given IV",
"name": "Romidepsin",
... | [
{
"design_group_description": "Participants receive romidepsin IV over 4 hours on days 1 and 8 or day 8 of cycle 1 and days 1 and 8 of subsequent cycles and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity."... | [
"Recurrent Anaplastic Large Cell Lymphoma",
"Recurrent Angioimmunoblastic T-Cell Lymphoma",
"Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma",
"Recurrent Mycosis Fungoides",
"Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
"Refractory Anaplastic Large Cell Lymphoma",
"Refractory Angioimmu... | [
"The University of Texas MD Anderson Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "罗米地辛",
"lang": "CN"
},
{
"name": "Romidepsin",
"lang": "EN"
},
{
"name": "ロミデプシン",
"lang": "JP"
}
],
[
{
"name": "帕博利珠单抗",
"lang": "CN"
},
{
"name": "Pembrolizumab",
"lang": "EN"
},
{
"name... | [
{
"identifier_source": [
{
"code": "855554e2234e89d8eeeed248e222992a",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "TCL-275"
}
] |
NCT03625037 | [
{
"id_field": "org_study_id",
"id_value": [
"GCT3013-01"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2017-001748-36"
]
},
{
"id_domain": "CCMO",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value"... | https://clinicaltrials.gov/study/NCT03625037 | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma | The purpose of this trial is to measure the following in participants with relapsed and/or refractory B-cell lymphoma who receive epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20):<br/>* The dose schedule for epcoritamab<br/>* The side effects seen with epcoritamab<br/>* What the body does... | A Phase 1/2, Open-label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma | [
{
"description": "Administered as specified in the treatment arm.",
"name": "Epcoritamab",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"DuoBody®-CD3xCD20",
"EPKINLY™",
"GEN3013"
],
"type": "Biological"
}
] | [
{
"design_group_description": "Epcoritamab will be administered by subcutaneous injections in cycles of 28 days.",
"design_group_title": "Epcoritamab",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"i... | [
"DLBCL",
"High-grade B-cell Lymphoma (HGBCL)",
"Primary Mediastinal Large B-cell Lymphoma (PMBCL)",
"FL",
"MCL",
"Small Lymphocytic Lymphoma (SLL)",
"Marginal Zone Lymphoma (MZL)",
"Indolent B-cell Non-Hodgkin Lymphoma (iNHL)",
"Aggressive B-cell Non-Hodgkin Lymphoma (aNHL)"
] | [
"Genmab A/S"
] | [
"AbbVie, Inc."
] | [
[
{
"name": "艾可瑞妥单抗",
"lang": "CN"
},
{
"name": "Epcoritamab",
"lang": "EN"
},
{
"name": "エプコリタマブ(遺伝子組換え)",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "aa4d5e2882a84dae08aa2a05e28a5522",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "EPCORE NHL-1 FL"
},
{
"identifier_source": [
{
"code": "53004ee93a32a8ed9a25025e9eae595e",
"source": "CT_... |
NCT06621043 | [
{
"id_field": "org_study_id",
"id_value": [
"NTIRTT1"
]
}
] | https://clinicaltrials.gov/study/NCT06621043 | Assessing the Safety and Efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) in the Treatment of Rett Syndrome (RTT) | This 18-week open-label study examines the effectiveness of Full-Spectrum Medicinal Cannabis Plant Extract containing 0.08% THC (NTI164) in treating Rett syndrome (RTT) in children and young people. The study aims to determine the impact of NTI164 on RTT symptoms over a 16-week treatment period.<br/>Participants will s... | Assessing the Safety and Efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) in the Treatment of Rett Syndrome (RTT) | [
{
"description": "Full-Spectrum Medicinal Cannabis Plant Extract containing 0.08% THC, administered orally starting with a dose of 5 mg/kg, titrated up to 20 mg/kg based on tolerance, followed by a maintenance phase at the maximum tolerated dose, and concluding with a gradual dose reduction.",
"name": "NTI1... | [
{
"design_group_description": "Participants in this arm receive Full-Spectrum Medicinal Cannabis Plant Extract containing 0.08% THC (NTI164), targeted at treating symptoms of Rett syndrome (RTT) in children and young people. The intervention starts with a daily initial dose of 5 mg/kg, which is increased gradua... | [
"Rett Syndrome"
] | [
"Fenix Innovation Group Pty, Ltd."
] | [
"Neurotech International Ltd."
] | [
[
{
"name": "NTI-164",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "89045958dd2a24e288da53aa22ea88ad",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "NTIRTT1"
}
] |
NCT05083481 | [
{
"id_field": "org_study_id",
"id_value": [
"1570-CL-0101"
]
},
{
"id_domain": "jRCT",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"jRCT2031220527"
]
},
{
"id_domain": "Merck Sharp & Dohme LLC",
"id_field": "secondary_id",
... | https://clinicaltrials.gov/study/NCT05083481 | A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors | Immune therapies work with the body's immune system to treat a number of cancers. They work with T-cells, a type of white blood cell, to target and attack specific tumors. However, some tumors can become resistant to attack by T-cells over time. They do this by sending "off" signals to T-cells. The researchers are find... | A Phase 1/2 Study of ASP1570 as Monotherapy and in Combination With Pembrolizumab and/or Standard Therapies Including Chemotherapy and/or Immunotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | [
{
"description": "Oral tablet",
"name": "ASP1570",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Intravenous Infusion",
"name": "pembrolizumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"KEYTRUDA®"
... | [
{
"design_group_description": "Participants will receive daily dose of ASP1570 in a 21-day cycle.",
"design_group_title": "ASP1570 Monotherapy Dose Escalation (Part 1)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
... | [
"Advanced Solid Tumors"
] | [
"Astellas Pharma Global Development, Inc."
] | [
"Merck Sharp & Dohme LLC"
] | [
[
{
"name": "曲氟尿苷替匹嘧啶",
"lang": "CN"
},
{
"name": "Tipiracil Hydrochloride/Trifluridine",
"lang": "EN"
},
{
"name": "トリフルリジン/チピラシル塩酸塩",
"lang": "JP"
}
],
[
{
"name": "ASP-1570",
"lang": "EN"
}
],
[
{
"name": "亚叶酸钙",
... | null |
NCT06056323 | [
{
"id_field": "org_study_id",
"id_value": [
"HB0045-01"
]
},
{
"id_field": "nct_alias",
"id_value": [
"NCT05944276"
]
}
] | https://clinicaltrials.gov/study/NCT06056323 | A Study of HB0045 Injection in Patients With Advanced Solid Tumors | This is a phase I/II, open-label, multicenter study . During the study, subjects will be evaluated for safety, toxicity, tolerability, PK/PD, immunogenicity, biomarkers, and antitumor activity of HB0045. The phase I study will enroll up to 54 subjects with advanced solid tumors who have progressed on or after standard ... | A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0045 in Patients With Advanced Solid Tumors | [
{
"description": "Patients will be assigned to dose regimens in the order of enrollment and receive their assigned fixed dose of HB0045 via intravenous infusion, Q3W.",
"name": "HB0045 Drug Product",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"fixed dose combination... | [
{
"design_group_description": "HB0045 IV every 3 weeks (q3w)",
"design_group_title": "HB0045",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Patients will be assigned to d... | [
"Solid Tumor, Adult"
] | [
"Shanghai Huaaotai Biopharmaceutical Co., Ltd."
] | [
"The University of Texas MD Anderson Cancer Center",
"Dana-Farber Cancer Institute, Inc.",
"Gabrail Cancer Center Research LLC"
] | [
[
{
"name": "HB0045",
"lang": "EN"
}
]
] | null |
NCT02244463 | [
{
"id_field": "org_study_id",
"id_value": [
"14-223"
]
}
] | https://clinicaltrials.gov/study/NCT02244463 | A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer | This research study is a phase I/II study of MLN0128 in metastatic anaplastic thyroid cancer(ATC) and incurably poorly differentiated or radioidodine refractory differentiated thyroid cancer (DTC).<br/>Due to changes in the manufacturing process which resulted in increased absorption of MLN0128 from capsules, a run-in ... | A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer | [
{
"name": "MLN0128",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"INK128",
"Sapanisertib"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Phase I Dose Level 1 participants receive MLN0128 3 mg orally, daily for 28 days. Participants are treated until disease progression or withdrawal of consent.",
"design_group_title": "Phase I: Dose Level 1 (PI DL1)",
"design_group_type": "Experimental",
"design_group_t... | [
"Anaplastic Thyroid Cancer",
"Thyroid Cancer",
"Differentiated Thyroid Cancer"
] | [
"Dana-Farber Cancer Institute, Inc."
] | [
"Millennium Pharmaceuticals, Inc."
] | [
[
{
"name": "Sapanisertib",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "a5223d0aa89822e93ad0493a0e228d8e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "phase I/II trial of sapanisertib"
}
] |
NCT04886167 | [
{
"id_field": "org_study_id",
"id_value": [
"CTBH-01-2021"
]
}
] | https://clinicaltrials.gov/study/NCT04886167 | Dysport Dose-Ranging Treatment of Platysmal Bands | This is a double-blinded, dose-ranging study in the US to assess the efficacy, safety, and duration of response of abobotulinumtoxinA for the treatment of moderate to severe platysmal bands. | A Dose-Ranging Study to Evaluate the Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Moderate to Severe Platysmal Bands | [
{
"description": "Injection of platysmal bands.",
"name": "AbobotulinumtoxinA",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Dysport"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Treatment of platysmal bands using a total of 120 U abobotulinumtoxinA. This will involve 24 injection sites (6 injections per each of 4 platysmal bands), with each injection site receiving 0.025mL (5 U).<br/>At the 14 day visit, an optional touch-up using up to 90 U of abobotulin... | [
"Platysma Bands"
] | [
"Clinical Testing of Beverly Hills"
] | [
"Galderma Holding SA"
] | [
[
{
"name": "A型肉毒杆菌毒素（Ipsen Biopharm Ltd）",
"lang": "CN"
},
{
"name": "AbobotulinumtoxinA (Ipsen Biopharm Ltd)",
"lang": "EN"
}
]
] | null |
NCT00412243 | [
{
"id_field": "org_study_id",
"id_value": [
"2005-0552"
]
}
] | https://clinicaltrials.gov/study/NCT00412243 | Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients | The goal of this clinical research study is to find the highest tolerable dose of the drugs clofarabine and cyclophosphamide that can be given together in the treatment of relapsed or refractory ALL. The safety of the combination treatment will also be studied.<br/>Objectives:<br/>Phase I:<br/>1. To establish toxicitie... | Phase I/II Study of Clofarabine Plus Cyclophosphamide for Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL) | [
{
"description": "40 mg/m^2 Daily for 3 Days",
"name": "Clofarabine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Clolar",
"Clorarex"
],
"type": "Drug"
},
{
"description": "Beginning dose 200 mg/m^2 every 12 hours for 3 days",
"name": "Cycl... | [
{
"design_group_description": "Clofarabine 40 mg/m^2 daily for 3 Days + Cyclophosphamide starting 200 mg/m^2 every 12 hours for 3 days",
"design_group_title": "Clofarabine + Cyclophosphamide",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",... | [
"Burkitt's Lymphoma",
"Lymphoblastic Lymphoma",
"Acute Lymphoblastic Leukemia"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"Genzyme Corp."
] | [
[
{
"name": "氯法拉滨",
"lang": "CN"
},
{
"name": "Clofarabine",
"lang": "EN"
},
{
"name": "クロファラビン",
"lang": "JP"
}
],
[
{
"name": "环磷酰胺",
"lang": "CN"
},
{
"name": "Cyclophosphamide",
"lang": "EN"
},
{
"n... | null |
NCT00458237 | [
{
"id_field": "org_study_id",
"id_value": [
"06-124"
]
}
] | https://clinicaltrials.gov/study/NCT00458237 | Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer | The purpose of this research study is to determine the safety of RAD001 and the highest dose of this drug that can be given to people with HER2-positive metastatic breast cancer safely in combination with trastuzumab. RAD001 has been used in patients with severe rheumatoid arthritis, in recipients of solid-organ transp... | A Brief Dose Escalation Followed by a Phase 2 Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer | [
{
"description": "Everolimus is being administered orally 7 days per week.",
"name": "Everolimus",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"RAD001"
],
"type": "Drug"
},
{
"description": "Trastuzumab is being administered at a dose of 6 mg/kg intra... | [
{
"design_group_description": "Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus 5 mg by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity.",
"design_group_title": "Ph I... | [
"Breast Cancer"
] | [
"Beth Israel Deaconess Medical Center, Inc."
] | [
"Novartis Pharmaceuticals Corp.",
"Dana-Farber Cancer Institute, Inc."
] | [
[
{
"name": "曲妥珠单抗",
"lang": "CN"
},
{
"name": "Trastuzumab",
"lang": "EN"
},
{
"name": "トラスツズマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "依维莫司",
"lang": "CN"
},
{
"name": "Everolimus",
"lang": "EN"
},
{
... | null |
NCT02913417 | [
{
"id_field": "org_study_id",
"id_value": [
"Uveal Melanoma IIP"
]
}
] | https://clinicaltrials.gov/study/NCT02913417 | Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases | Reports to date show limited efficacy of immunotherapy for uveal melanoma. Recent experimental and clinical evidence suggests synergy between radiation therapy and immunotherapy. The investigators will explore this synergy with a feasibility study of 26 patients with uveal melanoma and hepatic metastases who will recei... | A Feasibility Study of Sequential Hepatic Internal Radiation and Systemic Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastatic to Liver. | [
{
"description": "Patient treatment will consist of three parts: first, selective internal radiation with SIR-Spheres Yttrium-90 microspheres with dosage per package insert , reduced to give 35cGymax to normal liver; second, concurrent ipilimumab 1mg/kg and nivolumab 1mg/kg every 3 weeks for 4 doses (immunother... | [
{
"design_group_description": "SIR-Spheres Yttrium 90 will be given by injection into the hepatic artery in two treatments, one for each lobe. 3-5 weeks later patients receive concurrent ipilimumab 1mg/kg q 3 wk x 4 and nivolumab 3mg/kg q 3 weeks x 4, all followed by nivolumab 240mg/kg q 2 weeks or 480 mg q 4 w... | [
"Uveal Melanoma",
"Hepatic Metastases"
] | [
"California Pacific Medical Center Research Institute"
] | [
"The University of Chicago",
"Sidney Kimmel Medical College",
"California Pacific Medical Center"
] | [
[
{
"name": "伊匹木单抗",
"lang": "CN"
},
{
"name": "Ipilimumab",
"lang": "EN"
},
{
"name": "イピリムマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "纳武利尤单抗",
"lang": "CN"
},
{
"name": "Nivolumab",
"lang": "EN"
},
{
... | null |
NCT06495307 | [
{
"id_field": "org_study_id",
"id_value": [
"RHPRG4-OGVHD-001"
]
},
{
"id_field": "secondary_id",
"id_value": [
"RHPRG4-OGVHD-001"
]
}
] | https://clinicaltrials.gov/study/NCT06495307 | RHPRG4 FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD) | rhPRG4-GVHD-001 is a prospective multi-center study conducted in Australia to evaluate the safety and efficacy of topically-applied rhPRG4 in subjects with moderate to severe dry eye secondary to chronic GVHD. | A PHASE I PROSPECTIVE OPEN LABEL STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD) | [
{
"description": "Sterile isotonic aqueous solution containing rhPRG4 (450 µg/mL) for topical administration, 10 mM sodium phosphate, 150 mM sodium chloride & 0.01% polysorbate 20 at pH 7.2. In all subjects, both eyes will be treated",
"name": "rhPRG4",
"normalized_type": "3d1aa88261d64c038413723970f2b5... | [
{
"design_group_title": "Treatment",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Sterile isotonic aqueous solution containing rhPRG4 (450 µg/mL) for topical administration, ... | [
"Ocular Graft-versus-host Disease"
] | [
"Lubris BioPharma"
] | [
"Lubris BioPharma"
] | [
[
{
"name": "Recombinant Human Proteoglycan 4(Lubris BioPharma)",
"lang": "EN"
}
]
] | null |
NCT07009158 | [
{
"id_field": "org_study_id",
"id_value": [
"TRAQ-6043701"
]
}
] | https://clinicaltrials.gov/study/NCT07009158 | Ketamine Assisted Psychotherapy for Treating Comorbid Chronic Pain and PTSD | The goal of this pilot study is to evaluate the feasibility of conducting a clinical trial assessing if ketamine infusions combined to mindfulness therapy works better than psychotherapy alone to treat chronic pain and PTSD in adults living with both conditions. The objectives of the pilot study are to 1) assess the fe... | Ketamine Assisted Psychotherapy to Improve Quality of Life in Veterans and Civilians With Comorbid Chronic Pain and Posttraumatic Stress Disorder: an Open-label Randomized Controlled Trial. | [
{
"description": "Ketamine hydrochloride (DIN: 02246795, 02246796) will be administered over 40-min intravenous (IV) infusion twice per week on non-consecutive days for the first two weeks of study treatment (four treatment sessions in total). We will use a standard dose of 0.5mg/kg which has demonstrated effic... | [
{
"design_group_description": "The Ketamine-assisted psychotherapy (KAP) group will receive 4 ketamine infusion treatments and 8 sessions of mindfulness therapy.",
"design_group_title": "KAP group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61... | [
"Chronic Pain",
"Posttraumatic Stress Disorder (PTSD)"
] | [
"Queen's University"
] | [
"Kingston Health Sciences Centre",
"Providence Care Hospital"
] | [
[
{
"name": "盐酸氯胺酮",
"lang": "CN"
},
{
"name": "Ketamine Hydrochloride",
"lang": "EN"
},
{
"name": "ケタミン塩酸塩",
"lang": "JP"
}
]
] | null |
NCT06598202 | [
{
"id_field": "org_study_id",
"id_value": [
"XMEC-2024-267-002"
]
},
{
"id_field": "acronym",
"id_value": [
"de-ALS"
]
}
] | https://clinicaltrials.gov/study/NCT06598202 | Exploring Nasal Drop Therapy With Small Extracellular Vesicles for ALS | This is a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial. The goal of this clinical trial is to evaluate the safety and preliminary efficacy of nasal drop exosomes derived from human umbilical cord blood mesenchymal stem cells (hUC-MSC-sEV-001) in amyotrophic lateral sclerosis. | An Exploratory Study on the Use of Intranasal Administration of Small Extracellular Vesicles for the Treatment of Amyotrophic Lateral Sclerosis | [
{
"description": "Exosomes derived from human umbilical cord blood mesenchymal stem cells for nasal drop (administered once daily, twice a week, for a total of two weeks, based on the recommended dose during the dose-escalation phase).",
"name": "exosomes derived from human umbilical cord blood mesenchymal ... | [
{
"design_group_description": "Patients in this arm will receive exosomes derived from human umbilical cord blood mesenchymal stem cells as a nasal drop, administered once daily, twice a week, for a total of two weeks.",
"design_group_title": "Exosomes group",
"design_group_type": "Experimental",
"d... | [
"Amyotrophic Lateral Sclerosis"
] | [
"Xuanwu Hospital Capital Medical University"
] | [
"Shengqi Medical Technology (Guangzhou) Co., Ltd."
] | [
[
{
"name": "HUC-MSC-sEV-001 Nasal Drops(Xuanwu Hospital )",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "de-ALS"
}
] |
NCT00863369 | [
{
"id_field": "org_study_id",
"id_value": [
"04115"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"P30CA033572"
]
},
{
"id_field": "secondary_id",
"id_value": [
"CHNMC-04115"
]
},
{
"id_field": "second... | https://clinicaltrials.gov/study/NCT00863369 | Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma | RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies... | A Phase I/II Study of VELCADE in Combination With Gemcitabine in Relapsed B-Cell Non-Hodgkin's Lymphoma | [
{
"description": "Given IV",
"name": "rituximab",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"IDEC-C2B8",
"IDEC-C2B8 monoclonal antibody",
"MOAB IDEC-C2B8",
"Mabthera",
"Rituxan"
],
"type": "Biological"
},
{
"description": "Gi... | [
{
"design_group_description": "Patients receive bortezomib IV, gemcitabine hydrochloride IV over 3-4 hours, and rituximab IV on days 1 and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.",
"design_group_title": "Treatment (bortezomib... | [
"Lymphoma"
] | [
"City of Hope National Medical Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "盐酸吉西他滨",
"lang": "CN"
},
{
"name": "Gemcitabine Hydrochloride",
"lang": "EN"
},
{
"name": "ゲムシタビン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "硼替佐米",
"lang": "CN"
},
{
"name": "Bortezomib",
"lang": "EN"
},
... | null |
NCT01211457 | [
{
"id_field": "org_study_id",
"id_value": [
"CYC682-11"
]
}
] | https://clinicaltrials.gov/study/NCT01211457 | Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) | This is a combination study to evaluate sapacitabine administered in alternating cycles with decitabine in previously untreated Acute Myeloid Leukemia (AML) or concomitantly with venetoclax in previously treated AML or MDS | A Phase I/II Combination Study of Sapacitabine in Acute Myeloid Leukemia or Myelodysplastic Syndromes | [
{
"description": "decitabine will be administered in alternating cycles with sapacitabine",
"name": "sapacitabine and decitabine (Part 1 - completed)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "sapacitabine will be administered concomitantly w... | [
{
"design_group_description": "decitabine will be administered in alternating cycles with sapacitabine",
"design_group_title": "Sapacitabine/decitabine (Part 1 - completed)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention... | [
"Acute Myeloid Leukemia",
"Myelodysplastic Syndromes"
] | [
"Bio Green Med Solution, Inc."
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
[
{
"name": "维奈克拉",
"lang": "CN"
},
{
"name": "Venetoclax",
"lang": "EN"
},
{
"name": "ベネトクラクス",
"lang": "JP"
}
],
[
{
"name": "地西他滨",
"lang": "CN"
},
{
"name": "Decitabine",
"lang": "EN"
}
],
[
{
"... | null |
NCT01848067 | [
{
"id_field": "org_study_id",
"id_value": [
"13P.128"
]
},
{
"id_domain": "CCRRC",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"2013-02"
]
},
{
"id_domain": "JeffTrial Number",
"id_field": "secondary_id",
"id_type": "Other ... | https://clinicaltrials.gov/study/NCT01848067 | Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | This phase I/II trial studies the side effects and best dose of alisertib when given together with abiraterone acetate and prednisone and to see how well it works in treating patients with hormone-resistant prostate cancer. Alisertib and abiraterone acetate may stop the growth of tumor cells by blocking some of the enz... | A Phase I/II Study of Alisertib in Combination With Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer After Progression on Abiraterone | [
{
"description": "Given PO",
"name": "Alisertib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"MLN8237"
],
"type": "Drug"
},
{
"description": "Given PO",
"name": "Abiraterone acetate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
... | [
{
"design_group_description": "Patients receive alisertib PO BID on days 1-7, abiraterone acetate PO daily, and prednisone PO BID. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.",
"design_group_title": "Treatment (alisertib, abiraterone acetate, prednisone)",
... | [
"Adenocarcinoma of the Prostate",
"Hormone-resistant Prostate Cancer",
"Recurrent Prostate Cancer",
"Stage IV Prostate Cancer"
] | [
"Sidney Kimmel Cancer Center at Thomas Jefferson University"
] | [
"Millennium Pharmaceuticals, Inc."
] | [
[
{
"name": "Alisertib",
"lang": "EN"
}
],
[
{
"name": "泼尼松",
"lang": "CN"
},
{
"name": "Prednisone",
"lang": "EN"
}
],
[
{
"name": "醋酸阿比特龙",
"lang": "CN"
},
{
"name": "Abiraterone acetate",
"lang": "EN"
},
... | null |
NCT06084104 | [
{
"id_field": "org_study_id",
"id_value": [
"DZ2022E0007"
]
}
] | https://clinicaltrials.gov/study/NCT06084104 | DZD9008 PK Study in Hepatic Impairment Subjects | This study will investigate the pharmacokinetics, safety, and tolerability of DZD9008 in subjects with hepatic impairment compared to subjects with normal hepatic function | A Phase 1, Single-Dose, Non-Randomized, Open Label Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of DZD9008 | [
{
"description": "A single oral dose of 200mg DZD9008",
"name": "DZD9008",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "A single oral dose of 200mg DZD9008",
"name": "DZD9008",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"t... | [
{
"design_group_description": "Subjects with hepatic impairment",
"design_group_title": "Hepatic impairment",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "A single oral d... | [
"Hepatic Impairment"
] | [
"Dizal (Jiangsu) Pharmaceutical Co., Ltd."
] | [
"PPD Development LP"
] | [
[
{
"name": "舒沃替尼",
"lang": "CN"
},
{
"name": "Sunvozertinib",
"lang": "EN"
}
]
] | null |
NCT04219163 | [
{
"id_field": "org_study_id",
"id_value": [
"H-43516-CARMEN"
]
},
{
"id_domain": "CPRIT",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"52988-C1"
]
}
] | https://clinicaltrials.gov/study/NCT04219163 | Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen | Patients eligible for this study have a type of blood cancer Acute Myeloid Leukemia (AML) which has come back or has not gone away after treatment.<br/>The body has different ways of fighting disease and infection, and this research study combines two different ways of fighting cancer with antibodies and T cells with t... | Chimeric Antigen Receptor T-cells for The Treatment of Acute Myeloid Leukemia Expressing CLL-1 Antigen | [
{
"description": "Dose escalation study with 3 dose levels:<br/>DL1: 1x10^7 cells/m2, DL2: 3x10^7 cells/m2, DL3: 1x10^8 cells/m2<br/>If excessive dose limiting toxicity attributed to the product occurs at dose level one, we will request permission from FDA to treat at dose level -1: 5×10^6 cells/m2",
"name"... | [
{
"design_group_description": "Group A",
"design_group_title": "CLL-1.CAR",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Dose escalation study with 3 dose levels:<br/>DL1... | [
"Acute Myeloid Leukemia"
] | [
"Baylor College of Medicine"
] | [
"Center For Cell & Gene Therapy",
"The Methodist Hospital Research Institute"
] | [
[
{
"name": "CLL-1.CAR T cell therapy(Baylor College of Medicine)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "e20aed52225e298e24a952dd43a5e80e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "CARMEN"
}
] |
NCT01358721 | [
{
"id_field": "org_study_id",
"id_value": [
"CA209-009"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2011-005379-18"
]
}
] | https://clinicaltrials.gov/study/NCT01358721 | Phase I Biomarker Study (BMS-936558) | The purpose of this study is to evaluate the pharmacodynamic and biologic properties of BMS-936558 in subjects with metastatic renal cell carcinoma. | An Exploratory Study to Investigate the Immunomodulatory Activity of Various Dose Levels of Anti Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Subjects With Metastatic Clear Cell Renal Cell Carcinoma (RCC). | [
{
"description": "Solution, Intravenous infusion, 0.3 mg/kg, Every 3 weeks, Indefinitely depending on response",
"name": "BMS-936558 (Anti-PD-1)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Solution, Intravenous infusion, 2 mg/kg, Every 3 weeks... | [
{
"design_group_title": "Arm 1: BMS-936558",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Solution, Intravenous infusion, 0.3 mg/kg, Every 3 weeks, Indefinitely depending on ... | [
"Renal Cell Carcinoma"
] | [
"Bristol Myers Squibb Co."
] | [
"Ono Pharma USA, Inc."
] | [
[
{
"name": "纳武利尤单抗",
"lang": "CN"
},
{
"name": "Nivolumab",
"lang": "EN"
},
{
"name": "ニボルマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "2ed229288a284e3a9a9959e225a5292a",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "d8a02ad5588ee4240e5e2259ed394249",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "Che... |
NCT04138888 | [
{
"id_field": "org_study_id",
"id_value": [
"PTL-P0-847"
]
}
] | https://clinicaltrials.gov/study/NCT04138888 | A Bioequivalence Study of Two Different Formulations of Olmesartan Medoxomil/ Hydrochlorothiazide After a Single Oral Dose Administration Under Fasting Conditions | This single dose study was designed in accordance with EMA (the European Medicines Agency) regulatory guidelines, with the aim of characterizing the bioavailability of olmesartan medoxomil/ hydrochlorothiazide in the two formulations (Olmesartan Medoxomil/ Hydrochlorothiazide (HCTZ), 40 mg/ 25 mg film-coated tablets (M... | Single Dose Crossover Comparative Bioavailability Study of Olmesartan Medoxomil/Hydrochlorothiazide 40 mg/25 mg Film-Coated Tablets in Healthy Adult Subjects / Fasting State | [
{
"description": "Olmesartan Medoxomil/Hydrochlorothiazide is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.",
"name": "Olmesartan Medoxomil/Hydrochlorothiazide 40 Mg/25 Mg film-coated tablets for oral use",
... | [
{
"design_group_description": "16 subjects assigned to the sequence AB will receive a single 40 mg/25 mg dose of the test product Olmesartan Medoxomil/ Hydrochlorothiazide (1 x 40 mg/ 25 mg tablet), marked as A in the sequence, in Period 1 and a single 40 mg/25 mg dose of the reference product Olmetec® Plus (1 ... | [
"Bioequivalence"
] | [
"Pharmtechnology, LLC"
] | [
"Altasciences Co., Inc."
] | [
[
{
"name": "奥美沙坦酯氢氯噻嗪",
"lang": "CN"
},
{
"name": "Hydrochlorothiazide/Olmesartan Medoxomil",
"lang": "EN"
}
]
] | null |
NCT02604498 | [
{
"id_field": "org_study_id",
"id_value": [
"XCNN-150830-1"
]
}
] | https://clinicaltrials.gov/study/NCT02604498 | Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Moderate Impaired Hepatic Function | This is a single center, open-label, non-randomized, 1:1 parallel control and single dose administration study design. Healthy subjects will be matched to moderate hepatic function impaired (Child-Pugh B，7-9) subjects in age, gender and weight as parallel control, which matches healthy with normal hepatic function acco... | Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Moderate Impaired Hepatic Function | [
{
"description": "Single dose 500mg oral",
"name": "Nemonoxacin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Nemonoxacin Malate Capsules"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Subject with Moderate Impaired Hepatic Function. Nemonoxacin Malate Capsules 500mg single dose oral.",
"design_group_title": "Liver function impaired",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"inte... | [
"Liver Dysfunction"
] | [
"Zhejiang Medicine Co., Ltd."
] | [
"Shanghai Huashan Hospital"
] | [
[
{
"name": "苹果酸奈诺沙星",
"lang": "CN"
},
{
"name": "Nemonoxacin Malate",
"lang": "EN"
}
]
] | null |
NCT00527761 | [
{
"id_field": "org_study_id",
"id_value": [
"2003-1037"
]
}
] | https://clinicaltrials.gov/study/NCT00527761 | Taxotere/Temodar/Cisplatin Study in Melanoma Patients | Primary Objective:<br/>1. To determine the maximum tolerated dose of chemotherapy using Taxotere, Temodar, Cisplatin (TTC) in patients with metastatic melanoma.<br/>Secondary Objectives:<br/>1. To determine the toxicity of chemotherapy using Taxotere, Temodar, Cisplatin (TTC) in patients with metastatic melanoma<br/>2.... | Phase I Study of TTC (Taxotere/Temodar/Cisplatin) in Metastatic Melanoma Patients | [
{
"description": "20 mg in 500 ml of normal saline by vein over 60 minutes daily for 4 days starting on day 1 of chemotherapy.",
"name": "Cisplatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"CDDP",
"Platinol",
"Platinol-AQ"
],
"type": "Drug"
... | [
{
"design_group_title": "Temozolomide, Docetaxel + Cisplatin",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Starting dose 20 mg by vein over 1 hour, once a week, for three we... | [
"Metastatic Melanoma"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"Aventis Pharmaceuticals, Inc."
] | [
[
{
"name": "替莫唑胺",
"lang": "CN"
},
{
"name": "Temozolomide",
"lang": "EN"
},
{
"name": "テモゾロミド",
"lang": "JP"
}
],
[
{
"name": "顺铂",
"lang": "CN"
},
{
"name": "Cisplatin",
"lang": "EN"
},
{
"name": "シス... | null |
NCT02921061 | [
{
"id_field": "org_study_id",
"id_value": [
"9713"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2016-01401"
]
},
{
"id_domain": "Fred Hutch/University of Washing... | https://clinicaltrials.gov/study/NCT02921061 | Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS | This phase I/II trial studies the side effects and best dose of decitabine when given together with filgrastim, cladribine, cytarabine, and mitoxantrone hydrochloride in treating patients with acute myeloid leukemia or myelodysplastic syndrome that is newly diagnosed, has come back or has not responded to treatment. Dr... | Phase 1/2 Study of Concurrent Decitabine in Combination With G-CSF, Cladribine, Cytarabine, and Mitoxantrone (G-CLAM) in Adults With Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) | [
{
"description": "Given IV",
"name": "Cladribine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"2-CdA",
"2CDA",
"CdA",
"Cladribina",
"Leustat",
"Leustatin",
"Leustatine",
"RWJ-26251"
],
"type": "Drug"
},
{
"de... | [
{
"design_group_description": "INDUCTION: Patients receive decitabine IV over 1 hour on days 1-10. Patients also receive filgrastim SC on days 0-5, cladribine IV over 2 hours on days 1-5, cytarabine IV over 2-4 hours on days 1-5, and mitoxantrone hydrochloride IV over 60 minutes on days 1-3.<br/>RE-INDUCTION: P... | [
"Mixed Phenotype Acute Leukemia",
"Previously Treated Myelodysplastic Syndrome",
"Recurrent Adult Acute Myeloid Leukemia",
"Recurrent High Risk Myelodysplastic Syndrome",
"Refractory Acute Myeloid Leukemia",
"Refractory High Risk Myelodysplastic Syndrome",
"Untreated Adult Acute Myeloid Leukemia"
] | [
"Fred Hutchinson Cancer Research Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "克拉屈滨",
"lang": "CN"
},
{
"name": "Cladribine",
"lang": "EN"
},
{
"name": "クラドリビン",
"lang": "JP"
}
],
[
{
"name": "非格司亭 （安进）",
"lang": "CN"
},
{
"name": "Filgrastim (Amgen)",
"lang": "EN"
},
{
... | null |
NCT02038972 | [
{
"id_field": "org_study_id",
"id_value": [
"434269"
]
}
] | https://clinicaltrials.gov/study/NCT02038972 | Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss | To determine if autologous human umbilical cord blood infusion in children with acquired hearing loss is safe, feasible, improves inner ear function, audition and language development. | Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss | [
{
"description": "The subjects autologous stem cells banked at Cord Blood Registry will be infused intravenously by gravity.",
"name": "Autologous Stem Cells",
"normalized_type": "288887f0545745558ff1ab1c85757552",
"other_name": [
"Cell based therapy"
],
"type": "Genetic"
}
] | [
{
"design_group_description": "A single dose of intravenously administered autologous hUCB will be done. The minimum acceptable dose will be 6x10 6th mononuclear cells/kilogram body weight. The hUCB reanimation, cell processing and product infusion will occur at Florida Hospital for Children and the Florida Hos... | [
"Sensorineural Hearing Loss"
] | [
"AdventHealth Waterman"
] | [
"CBR Systems, Inc."
] | [
[
{
"name": "Autologous Human Umbilical Cord Blood(AdventHealth)",
"lang": "EN"
}
]
] | null |
NCT00540579 | [
{
"id_field": "org_study_id",
"id_value": [
"SCRI GI 105"
]
},
{
"id_field": "secondary_id",
"id_value": [
"PO-PANC-PI-009"
]
}
] | https://clinicaltrials.gov/study/NCT00540579 | CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas | Because the activity of CC-4047 addresses numerous mechanisms of carcinoma growth inhibition - including, but not limited to anti-angiogenesis - CC-4047 has been selected for development as part of induction chemotherapy regimens for solid tumors. This study in pancreatic cancer is designed to determine the appropriate... | A Phase I/II Study of CC-4047 in Combination With Gemcitabine in Subjects With Untreated Advanced Carcinoma of the Pancreas | [
{
"description": "Phase 1: Subjects will be enrolled in dose-escalating cohorts to be treated with CC-4047 on days 1-21 Phase II: Subjects will be enrolled to receive oral CC-4047 at the MTD days 1 - 21",
"name": "Pomalidomide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
... | [
{
"design_group_description": "All patients received gemcitabine 1000 mg/m2 IV on days 1, 8, and 15 of a 28 day cycle. Pomalidomide was administered orally on days 1-21 at doses escalated from 2 mg to 10 mg daily.",
"design_group_title": "Intervention",
"design_group_type": "Experimental",
"design_g... | [
"Pancreatic Cancer"
] | [
"Scri Development Innovations LLC"
] | [
"Celgene Corp."
] | [
[
{
"name": "盐酸吉西他滨",
"lang": "CN"
},
{
"name": "Gemcitabine Hydrochloride",
"lang": "EN"
},
{
"name": "ゲムシタビン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "泊马度胺",
"lang": "CN"
},
{
"name": "Pomalidomide",
"lang": "EN"
},
... | null |
NCT00639392 | [
{
"id_field": "org_study_id",
"id_value": [
"VCU-PT101439"
]
}
] | https://clinicaltrials.gov/study/NCT00639392 | Phase 1 Study of Zoledronic Acid in Sickle Cell Disease | The long-term goal of this study is to learn if Zoledronic Acid can prevent or reduce pain in sickle cell disease. The goal of this study is to learn about the safety of Zoledronic Acid in persons with sickle cell disease who experience chronic pain requiring medical treatment or use of narcotics. | Phase 1 Study of Zoledronic Acid in Sickle Cell Disease | [
{
"description": "Patients will receive a single dose of placebo administered by vein over about 15 minutes. Placebo is mostly water without Zoledronic Acid.",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Patients will receive ... | [
{
"design_group_description": "Patients will receive a single dose of Zoledronic Acid or placebo. The chances that a subject will receive placebo are 1 out of 3.",
"design_group_title": "2",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163e... | [
"Sickle Cell Disease"
] | [
"Virginia Commonwealth University"
] | [
"Novartis AG"
] | [
[
{
"name": "唑来膦酸",
"lang": "CN"
},
{
"name": "Zoledronic Acid",
"lang": "EN"
},
{
"name": "ゾレドロン酸水和物",
"lang": "JP"
}
]
] | null |
NCT02421367 | [
{
"id_field": "org_study_id",
"id_value": [
"S-14-13"
]
},
{
"id_domain": "WRAIR",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"WRAIR # 2195"
]
},
{
"id_domain": "GSK",
"id_field": "secondary_id",
"id_type": "Other Identifi... | https://clinicaltrials.gov/study/NCT02421367 | Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults | This study is being conducted to evaluate the safety and immunogenicity and antibody persistence of the candidate dengue vaccine. | A Phase 1/2, Randomized, Observer-blind Study of Varying Injection Schedules of a Tetravalent Dengue Virus Purified Inactivated Vaccine (TDENV-PIV) With AS03B Adjuvant and Placebo in Healthy Adults in the US | [
{
"description": "Tetravalent dengue virus purified inactivated vaccine (1 µg/virus type)",
"name": "TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_description": "The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.<br/>The placebo is sodium chloride.<br/>TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possib... | [
"Dengue"
] | [
"U S Army Medical Research & Development Command"
] | [
"Walter Reed Army Institute of Research",
"GSK Plc"
] | [
[
{
"name": "Tetravalent dengue virus purified inactivated vaccine(Walter Reed Army Institute of Research)",
"lang": "EN"
}
]
] | null |
NCT01078142 | [
{
"id_field": "org_study_id",
"id_value": [
"341"
]
},
{
"id_field": "acronym",
"id_value": [
"BERT"
]
}
] | https://clinicaltrials.gov/study/NCT01078142 | Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma | This is a multicenter, open label, single arm, phase I/II study. There will be no placebo usage within this trial.<br/>Phase I:<br/>Primary: To establish a maximum tolerated dose of the addition of Temsirolimus to a regimen of Bendamustine and Rituximab (BERT) in patients with relapsed follicular lymphoma and mantle ce... | A Phase I/II Trial to Evaluate the Safety, Feasibility and Efficacy of the Addition of Temsirolimus to a Regimen of Bendamustine and Rituximab for the Treatment of Patients With Follicular Lymphoma or Mantle Cell Lymphoma in First to Third Relapse | [
{
"description": "Phase I:<br/>Temsirolimus 25 - 50 - 75mg, day 1,8,15 Bendamustin 90/m2, day 1,2 Rituximab 375/m2, day 1 Phase II at established dose, repeat day 28-42 (max)",
"name": "Temsirolimus, Rituximab, Bendamustin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
... | [
{
"design_group_description": "Bendamustin, Rituximab, Temsirolimus",
"design_group_title": "Single arm",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Phase I:<br/>Temsir... | [
"Follicular Lymphoma",
"Mantle Cell Lymphoma"
] | [
"The Johannes Gutenberg University of Mainz"
] | [
"Mundipharma Pte Ltd.",
"Wyeth AB"
] | [
[
{
"name": "盐酸苯达莫司汀",
"lang": "CN"
},
{
"name": "Bendamustine Hydrochloride",
"lang": "EN"
},
{
"name": "ベンダムスチン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "利妥昔单抗",
"lang": "CN"
},
{
"name": "Rituximab",
"lang": "EN"
},... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "BERT"
}
] |
NCT05668741 | [
{
"id_field": "org_study_id",
"id_value": [
"VX21-522-001"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2022-000726-25"
]
},
{
"id_domain": "EU CT Number",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id... | https://clinicaltrials.gov/study/NCT05668741 | A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF) | The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy. | A Phase 1/2 Dose Escalation Study Evaluating the Safety, and Tolerability and Efficacy of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy | [
{
"description": "Oral inhalation using nebulizer.",
"name": "VX-522 mRNA therapy",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Tablet for oral administration.",
"name": "IVA",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"... | [
{
"design_group_description": "Participants grouped into different cohorts will receive a single ascending dose of VX-522.",
"design_group_title": "Single Ascending Dose (SAD)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervent... | [
"Cystic Fibrosis"
] | [
"Vertex Pharmaceuticals, Inc."
] | [
"Moderna, Inc."
] | [
[
{
"name": "艾伐卡托",
"lang": "CN"
},
{
"name": "Ivacaftor",
"lang": "EN"
}
],
[
{
"name": "VX-522",
"lang": "EN"
}
]
] | null |
NCT00314262 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB00024922"
]
}
] | https://clinicaltrials.gov/study/NCT00314262 | Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor | Evaluate effect on cells and patient response to study medications, assess side effects of these medications, and evaluate chemicals in cells that may tell how the drug works, before, and after receiving the study medications. | Phase I/II Study of Chemoprevention With Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Erlotinib (OSI-774, Tarceva) and Cyclooxygenase-2 (COX-2) Inhibitor (Celecoxib) in Premalignant Lesions of Head and Neck of Former Smokers | [
{
"description": "Erlotinib given orally, once daily (dose escalation from 50 mg, 75 mg, or 100 mg) continuously for 6 months in the phase I portion.<br/>Celecoxib given 400 mg orally BID continuously for 6 months.",
"name": "Erlotinib & Celecoxib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",... | [
{
"design_group_title": "Erlotinib & Celecoxib",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Erlotinib given orally, once daily (dose escalation from 50 mg, 75 mg, or 100 mg... | [
"Precancerous Conditions"
] | [
"Emory University"
] | [
"National Institutes of Health"
] | [
[
{
"name": "盐酸厄洛替尼",
"lang": "CN"
},
{
"name": "Erlotinib Hydrochloride",
"lang": "EN"
},
{
"name": "エルロチニブ塩酸塩",
"lang": "JP"
}
],
[
{
"name": "塞来昔布",
"lang": "CN"
},
{
"name": "Celecoxib",
"lang": "EN"
},
{... | null |
NCT03618134 | [
{
"id_field": "org_study_id",
"id_value": [
"17-001204"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2018-01214"
]
}
] | https://clinicaltrials.gov/study/NCT03618134 | Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner | This phase Ib/II trial studies the side effects and how well stereotactic body radiation therapy and durvalumab with or without tremelimumab before surgery work in treating participants with human papillomavirus positive oropharyngeal squamous cell cancer. Stereotactic body radiation therapy is a specialized radiation ... | Phase Ib/II Trial of Stereotactic Body Radiotherapy (SBRT) in Cominbation With Immunotherapy Prior to Transoral Robotic Surgery (TORS) for Human Papillomavirus Positive (HPV+) Squamous Cell Carcinoma of the Head and Neck (SCCHN) | [
{
"description": "Given IV",
"name": "Durvalumab",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Imfinzi",
"Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer",
... | [
{
"design_group_description": "Beginning day 0 of course 1, participants undergo stereotactic body radiation therapy 5 days a week for 1 week and receive durvalumab IV over 1 hour on days 0 and 27 in the absence of disease progression or unacceptable toxicity. Participants then undergo transoral robotic surgery... | [
"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8",
"Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
"Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
"Human Papillomavirus Positive... | [
"Jonsson Comprehensive Cancer Center"
] | [
"AstraZeneca PLC"
] | [
[
{
"name": "曲麦利尤单抗",
"lang": "CN"
},
{
"name": "Tremelimumab",
"lang": "EN"
},
{
"name": "トレメリムマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "度伐利尤单抗",
"lang": "CN"
},
{
"name": "Durvalumab",
"lang": "EN"
},
{
... | null |
NCT00879138 | [
{
"id_field": "org_study_id",
"id_value": [
"483-001"
]
}
] | https://clinicaltrials.gov/study/NCT00879138 | Efficacy and Safety of VA106483 in Elderly Males | A double blind, placebo-controlled, dose ranging study in males over the age of 65, who have a history of nocturia. The study will investigate pharmacodynamic outcomes (urine volumes and osmolality, circulating coagulation factors and haemodynamics) and pharmacokinetics, of both single and multiple oral doses of VA1064... | A Double-blind, Placebo-controlled Dose Response Study to Investigate Pharmacodynamics and Pharmacokinetics of Single and Repeated Oral Doses of VA106483 in Elderly Male Subjects | [
{
"name": "VA106483",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "Sugar pill",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_title": "Sugar pill",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
"intervention_name": "Sugar pill",
"intervention_type": "Drug",
"normalized_intervention_type": "3... | [
"Nocturia"
] | [
"Vantia Ltd."
] | [
"Veeda Clinical Research Ltd."
] | [
[
{
"name": "Fedovapagon",
"lang": "EN"
}
]
] | null |
NCT00516828 | [
{
"id_field": "org_study_id",
"id_value": [
"I186"
]
},
{
"id_domain": "NCI US - Physician Data Query",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"CAN-NCIC-IND186"
]
},
{
"id_domain": "PDQ",
"id_field": "secondary_id",
... | https://clinicaltrials.gov/study/NCT00516828 | Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | RATIONALE: Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the cancer. Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividin... | A Phase I/II Study of Sorafenib (BAY 43-9006) in Combination With Low Dose ARA-C (CYTARABINE) in Elderly Patients With AML or High-Risk MDS | [
{
"description": "subcutaneously twice daily from Day 1 to 10",
"name": "cytarabine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Cytarabine: subcutaneously twice daily from day 1 - 10. Sorafenib: Days 2-28; at the dose level assigned at registration. Sorafenib will be given orally twice daily.",
"design_group_title": "Sorafenib and Cytarabine",
"design_group_type": "Experimental",
"design_group_... | [
"Leukemia",
"Myelodysplastic Syndromes"
] | [
"NCIC Clinical Trials Group"
] | [
"Bayer AG"
] | [
[
{
"name": "阿糖胞苷",
"lang": "CN"
},
{
"name": "Cytarabine",
"lang": "EN"
},
{
"name": "シタラビン",
"lang": "JP"
}
]
] | null |
NCT01016600 | [
{
"id_field": "org_study_id",
"id_value": [
"09-1816 / 201101749"
]
}
] | https://clinicaltrials.gov/study/NCT01016600 | Azacitidine and Lenalidomide for Acute Myeloid Leukemia | Determine toxicity and remission rates of treatment with azacitidine and lenalidomide for patients with Acute Myeloid Leukemia | Phase I/II Trial of Azacitidine Plus Lenalidomide in the Treatment of Acute Myeloid Leukemia | [
{
"name": "Lenalidomide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Revlimid"
],
"type": "Drug"
},
{
"name": "Azacitidine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Vidaza"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Induction regimen (total 2 cycles)<br/>Lenalidomide 50 mg PO daily days 1-28<br/>Azacitidine 25 mg/m2 IV days 1-5<br/>Maintenance Regimen<br/>Lenalidomide 10 mg PO daily days 1-28<br/>Azacitidine 75 mg/m2 IV days 1-5",
"design_group_title": "Cohort 1",
"design_group_type":... | [
"Leukemia, Myeloid, Acute"
] | [
"Washington University School of Medicine"
] | [
"Celgene Corp."
] | [
[
{
"name": "来那度胺",
"lang": "CN"
},
{
"name": "Lenalidomide",
"lang": "EN"
},
{
"name": "レナリドミド水和物",
"lang": "JP"
}
],
[
{
"name": "阿扎胞苷",
"lang": "CN"
},
{
"name": "Azacitidine",
"lang": "EN"
},
{
"nam... | null |
NCT01283334 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB00040298"
]
},
{
"id_domain": "Other",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"WCI1761-09"
]
}
] | https://clinicaltrials.gov/study/NCT01283334 | A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer | The purpose of this study is to test the drug RAD001 in combination with other chemotherapy drugs, Carboplatin and Cetuximab. Because RAD001 has not been used in this combination before, it is not clear which dose will be best when used in combination.<br/>The investigators will test the safety of RAD001 in combination... | A Phase I/IIB Study of Combination Weekly Carboplatin, Cetuximab and Dose Escalation of RAD001 in Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) | [
{
"description": "Will be given as a 30 minutes intravenous (IV) infusion on days 1, 8, and 15 of each 28 day cycle. The starting dose of carboplatin will be area under the plasma-concentration time curve (AUC) = 2 mg/ml.min. Appropriate dose reductions will be done for toxicity for subsequent cycles.",
"na... | [
{
"design_group_description": "Treatment arm with carboplatin, cetuximab and RAD001",
"design_group_title": "A",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Will be give... | [
"Head and Neck Neoplasms",
"Cancer of the Head and Neck"
] | [
"Emory University"
] | [
"Novartis AG"
] | [
[
{
"name": "西妥昔单抗",
"lang": "CN"
},
{
"name": "Cetuximab",
"lang": "EN"
},
{
"name": "セツキシマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "卡铂",
"lang": "CN"
},
{
"name": "Carboplatin",
"lang": "EN"
},
{
"na... | null |
NCT05858814 | [
{
"id_field": "org_study_id",
"id_value": [
"RC1012-AML002"
]
}
] | https://clinicaltrials.gov/study/NCT05858814 | RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT | To evaluate the safety and tolerability of RC1012 injection infusion in AML Patients after Allo-HSCT | A Phase I/II Clinical Trial of RC1012 Injection for the Prevention of Relapse in AML Patients After Allogeneic Hematopoietic Stem Cell Transplantation | [
{
"description": "RC1012 injection (allo-DNT cells) are from healthy donors and have been proved to be safe and demonstrated potent cytotoxicity against AML blasts from AML patients in preclinical and preliminary clinical studies. Allo- DNT cells will be collected from healthy donors (NO MHC match needed) and i... | [
{
"design_group_description": "The trial is divided into two parts: Part A is a dose escalation trial with two dose groups (1.0×10^8 cells/kg, 1.5×10^8 cells/kg at day 0, day 28 and day 56), with 6-12 patients planned to be enrolled. Part B is a dose-expansion randomized controlled trial in which 40-60 patients... | [
"Acute Myeloid Leukemia"
] | [
"Guangdong Ruishun Biotechnology Co., Ltd."
] | [
"Anhui Shackle Hospital Co., Ltd."
] | [
[
{
"name": "RC-1012",
"lang": "EN"
}
]
] | null |
NCT07022964 | [
{
"id_field": "org_study_id",
"id_value": [
"BJGBYY-IIT-LCYJ-2025-032"
]
}
] | https://clinicaltrials.gov/study/NCT07022964 | CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas | This is a multi-center, open-label, non-randomized, single-arm clinical trial. Refractory/relapse T-NHL patients are treated with autologous and allogeneic CD5 CAR T-cell therapy. The primary objective is to prospectively evaluate the safety of CD5 CAR T cell bridging to HSCT in the treatment of r/r T-NHL. The primary ... | A Multicenter, Open-Label, Non-Randomized, Single-Arm Phase I/II Clinical Study of Autologous and New Donor CD7 CAR-T Cells for Relapsed or Refractory Mature T-Cell Lymphomas | [
{
"description": "Approximately 3-5 days prior to CD5 CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.",
"name": "CD5 CAR-T cells infusion",
"normalized_type": "3d1aa... | [
{
"design_group_description": "Enrolled patients were treated with anti-CD7 CAR-T cells, with or without allo-HSCT bridging.",
"design_group_title": "CD5 CAR-T therapy",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
... | [
"T-Cell Non-Hodgkin Lymphoma",
"T-cell Lymphoma (PTCL and CTCL)"
] | [
"Beijing Gaobo Hospital Co., Ltd."
] | [
"Ruijin Hospital"
] | [
[
{
"name": "CD5 CAR T cells(Beijing GoBroad Hospital/Beijing Boren Hospital)",
"lang": "EN"
}
]
] | null |
NCT01732640 | [
{
"id_field": "org_study_id",
"id_value": [
"J1266"
]
},
{
"id_domain": "JHMIRB",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"NA_00074085"
]
}
] | https://clinicaltrials.gov/study/NCT01732640 | A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC. | Trial Objectives:<br/>The objective is to investigate the efficacy and safety of afatinib with induction chemotherapy in primary unresected patients with locally advanced, HPV-negative, stage III or IVa/b HNSCC including oral cavity, oropharynx, hypopharynx, or larynx.<br/>Primary Objective Phase I The primary objectiv... | A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy Followed By Standard Chemoradiation In HPV-Negative or High-risk HPV-Positive Locally Advanced Stage III/IVa/IVb HNSCC | [
{
"description": "Afatinib will be supplied as film-coated tablets. Available dosage strengths will be 20, 30, or 40 mg. Tablets will be supplied in HDPE, child-resistant, tamper-evident bottles.",
"name": "Afatinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"N-[4... | [
{
"design_group_description": "Eligible patients will begin with a 14-day lead-in period with afatinib alone. This will be followed immediately by 2 cycles of induction chemotherapy (IC) with carboplatin AUC 6 IV Day 1, paclitaxel 175mg/m2 IV Day 1, and oral afatinib as a continuous daily dosing. Each cycle is ... | [
"Squamous Cell Carcinoma of the Head and Neck"
] | [
"The Sidney Kimmel Comprehensive Cancer Center"
] | [
"The Vanderbilt-Ingram Cancer Center",
"National Comprehensive Cancer Network, Inc."
] | [
[
{
"name": "马来酸阿法替尼",
"lang": "CN"
},
{
"name": "Afatinib Dimaleate",
"lang": "EN"
},
{
"name": "アファチニブマレイン酸塩",
"lang": "JP"
}
],
[
{
"name": "卡铂",
"lang": "CN"
},
{
"name": "Carboplatin",
"lang": "EN"
},
{
... | null |
NCT02944162 | [
{
"id_field": "org_study_id",
"id_value": [
"PG-0332"
]
}
] | https://clinicaltrials.gov/study/NCT02944162 | CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML | The purpose of this clinical trial is to study genetically engineered NK92 cell therapy in treating patients with CD33 positive acute myeloid leukemias that is relapsed (after stem cell transplantation or intensive chemotherapy) or refractory to further chemotherapy. | Clinical Investigation of Chimeric CD(Cluster of Differentiation)33 Antigen Receptor-modified NK92 Cells in Relapsed and/or Refractory Acute Myeloid Leukemias | [
{
"description": "The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD33 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD33.",
"name": "anti-CD33 CAR-NK cells",
"norma... | [
{
"design_group_description": "Enrolled patients will receive CAR-NK cells immunotherapy with a novel specific chimeric antigen receptor targeting CD33 antigen by infusion.",
"design_group_title": "CAR-NK Cell immunotherapy",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "7... | [
"Acute Myelogenous Leukemia",
"Acute Myeloid Leukemia",
"Acute Myeloid Leukemia With Maturation",
"Acute Myeloid Leukemia Without Maturation",
"ANLL"
] | [
"PersonGen BioTherapeutics (Suzhou) Co., Ltd."
] | [
"Hefei No. 1 People's Hospital"
] | [
[
{
"name": "Anti-CD33 CAR-NK92 cells (PersonGen Biomedicine)",
"lang": "EN"
}
]
] | null |
NCT04306354 | [
{
"id_field": "org_study_id",
"id_value": [
"U1111-1188-6555"
]
},
{
"id_domain": "Registro Brasileiro de Ensaios Clínicos",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"U1111-1188-6555"
]
},
{
"id_domain": "Plataforma Brasil",
... | https://clinicaltrials.gov/study/NCT04306354 | Use of Intranasal Oxytocin During Detoxification of Crack Cocaine | Randomized treatment control trial, double-blind, parallel, with two arms including ninety-six hospitalized women between 18 and 52 years. Those who agree to participate in the study and meet the eligibility criteria will be randomly allocated to one of the following experimental conditions:<br/>* Conventional oxytocin... | Randomized, Double-Blind, Placebo Controlled Study of Intranasal Oxytocin During Detoxification of Crack Cocaine | [
{
"description": "Oxytocin nasal spray 24 UI twice daily as adjunctive treatment to conventional treatment during 10 days of detoxification of crack cocaine",
"name": "Oxytocin nasal spray",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Nasal spra... | [
{
"design_group_description": "32 female cocaine users hospitalized for detoxification will receive six 4 IU jets of intranasal oxytocin twice daily (daily dose of 48 IU) as adjunctive treatment to conventional treatment from the eighth to seventeenth day of hospitalization (duration of oxytocin treatment of 10... | [
"Cocaine Withdrawal",
"Cocaine Smoking",
"Cocaine-Related Disorders"
] | [
"Pontifical Catholic University of Rio Grande Do Sul"
] | [
"Conselho Nacional de Desenvolvimento Cientifico e Tecnológico"
] | [
[
{
"name": "缩宫素",
"lang": "CN"
},
{
"name": "Oxytocin",
"lang": "EN"
},
{
"name": "オキシトシン",
"lang": "JP"
}
]
] | null |
NCT07113106 | [
{
"id_field": "org_study_id",
"id_value": [
"2024-516767-92-01"
]
},
{
"id_domain": "Inserm-ANRS MIE",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"ANRS0640s LKV-PAN-01 (PANCOV)"
]
},
{
"id_field": "acronym",
"id_value": [
... | https://clinicaltrials.gov/study/NCT07113106 | Dose Escalation Trial of CD40.Pan.CoV Vaccine, Adjuvanted or Not, as a Booster in Adult Healthy Volunteers | The clinical trial is a phase1/2a, open-label, dose-escalating, multicentre trial evaluating the safety and immunogenicity of the CD40.Pan.CoV vaccine, adjuvanted or not, as a booster injection in adult participants in France. 48 participants divided into 4 cohorts will be included in the trial.<br/>Primary objectives ... | A Phase 1/2a Multicenter Trial to Evaluate the Safety and Immunogenicity of the CD40.Pan.CoV Vaccine, Adjuvanted or Not, as a Booster in Adult Participants | [
{
"description": "SC Injection in deltoid of Low dose (LD; 0.25 mg) CD40.Pan.CoV vaccine non adjuvanted at Day 0.",
"name": "CD40.Pan.CoV Low dose(0.25mg)",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "SC injection in deltoid of LD (0.25 mg... | [
{
"design_group_description": "Injection of Low dose CD40.Pan.CoV vaccine non adjuvanted",
"design_group_title": "Cohort 1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "... | [
"Healthy Volunteers"
] | [
"ANRS Emerging infectious diseases"
] | [
"Institut National de la Santé et de la Recherche Médicale"
] | [
[
{
"name": "CD40.Pan.CoV Vaccine",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "PANCOV"
}
] |
NCT02236000 | [
{
"id_field": "org_study_id",
"id_value": [
"NSABP FB-10"
]
}
] | https://clinicaltrials.gov/study/NCT02236000 | A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer | This study is being done for the following reasons:<br/>* The study has two parts. The purpose of the first part (Phase I) of the study is to find out the highest dose of neratinib that can be given safely with T-DM1.<br/>* The purpose of the second part of the study (Phase II) is to find out whether the dose of nerati... | A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer | [
{
"description": "Dose-Escalation Phase (Part 1) - Neratinib Dose-escalation will proceed on the basis of DLT during Cycle 1 starting at 120 mg/day.<br/>Dose level 1: 120 mg/day; Dose level 2: 160 mg/day; Dose level 3: 200 mg/day; Dose level 4: 240 mg/day<br/>Dose-evaluation Phase (Part 2) - Patients will recei... | [
{
"design_group_title": "Neratinib and T-DM1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Dose-Escalation Phase (Part 1) - Neratinib Dose-escalation will proceed on the bas... | [
"Breast Cancer"
] | [
"NSABP Foundation, Inc."
] | [
"Puma Biotechnology, Inc."
] | [
[
{
"name": "恩美曲妥珠单抗",
"lang": "CN"
},
{
"name": "ADO-Trastuzumab Emtansine",
"lang": "EN"
},
{
"name": "トラスツズマブ エムタンシン（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "马来酸奈拉替尼",
"lang": "CN"
},
{
"name": "Neratinib maleate",
... | [
{
"identifier_source": [
{
"code": "0d8e485a4a22500ee24e23d82e8322a2",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "28252d0e32489853283e22e58285e843",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code":... |
NCT02335905 | [
{
"id_field": "org_study_id",
"id_value": [
"H-35130"
]
},
{
"id_domain": "Allergan",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"TEF-IT-43/IIT-2017-10048"
]
}
] | https://clinicaltrials.gov/study/NCT02335905 | Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children | This research study is looking at an antibiotic medicine, Ceftaroline Fosamil (Ceftaroline), which fights infections like the one the subject has. Ceftaroline is effective against S.aureus germs including those that are called Methicillin Resistant Staphylococcus aureus (MRSA.)<br/>Ceftaroline has been approved by the ... | Phase 1/2 Trial of Ceftaroline for the Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children | [
{
"description": "IV Ceftaroline fosamil 15 mg/kg (or 600 mg if > 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour) for children 2 years of age - 17 years of age (inclusive). IV Ceftarloine Fosamil 10 mg/kg infused 120 (± 10) minutes q8h (± 1 hour) for children 1 years of age - less than 2 years of age (inc... | [
{
"design_group_description": "IV Ceftaroline fosamil 15 mg/kg (or 600 mg if > 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour). The dose may vary with age.",
"design_group_title": "Ceftaroline Fosamil",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480... | [
"Hematogenously Acquired Staphylococcus Aureus Osteomyelitis",
"Bone Infection",
"Osteomyelitis"
] | [
"Baylor College of Medicine"
] | [
"Allergan UC"
] | [
[
{
"name": "醋酸头孢洛林酯",
"lang": "CN"
},
{
"name": "Ceftaroline Fosamil",
"lang": "EN"
}
]
] | null |
NCT02178722 | [
{
"id_field": "org_study_id",
"id_value": [
"INCB 24360-202/ ECHO-202"
]
}
] | https://clinicaltrials.gov/study/NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2. | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers (ECHO-202/KEYNOTE-037) | [
{
"description": "IV infusion",
"name": "MK-3475",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Oral daily dosing",
"name": "INCB024360",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Phase 1: MK-3475 + INCB024360 25 mg twice a day (BID) as starting dose, followed by dose escalations (Phase 1) until recommended phase 2 dose of INCB024360 is determined",
"design_group_title": "Phase 1: MK-3475 + INCB024360",
"design_group_type": "Experimental",
"desi... | [
"Microsatellite-instability (MSI) High Colorectal Cancer (CRC)",
"Endometrial Cancer",
"Head and Neck Cancer",
"Hepatocellular Carcinoma (HCC)",
"Gastric Cancer",
"Lung Cancer",
"Lymphoma",
"Renal Cell Carcinoma (RCC)",
"Ovarian Cancer",
"Solid Tumors",
"UC (Urothelial Cancer)",
"Melanoma",
... | [
"Incyte Corp."
] | [
"Merck Sharp & Dohme Corp."
] | [
[
{
"name": "帕博利珠单抗",
"lang": "CN"
},
{
"name": "Pembrolizumab",
"lang": "EN"
},
{
"name": "ペムブロリズマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "艾卡哚司他",
"lang": "CN"
},
{
"name": "Epacadostat",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "5282988050eeae55004e55ea842059aa",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "895a899e525a5ad08002aaaeea53d82a",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code":... |
NCT02449005 | [
{
"id_field": "org_study_id",
"id_value": [
"ELKE-90467"
]
},
{
"id_field": "acronym",
"id_value": [
"PerioRegen"
]
}
] | https://clinicaltrials.gov/study/NCT02449005 | Autologous Alveolar Bone Marrow Mesenchymal Stem Cells for the Reconstruction of Infrabony Periodontal Defects | Systemically healthy periodontitis patients are recruited from new referrals to the Department of Periodontology and Biology of Implants, AUTh. After completion of non-surgical periodontal treatment those subjects who have at least one interdental osseous defect with probing pocket depth and clinical attachment level o... | A Phase I/II Double-Blind Randomised Controlled Clinical Trial To Study The Safety and Efficacy Of A Novel Regenerative Treatment Of Infrabony Periodontal Defects Using Autologous Alveolar Bone-Marrow Mesenchymal Stem Cells (aBM-MSCs). | [
{
"description": "Xeno-free, clinical-grade, autologous alveolar bone marrow mesenchymal stem cells enriched with autologous fibrin glue and loaded into a commercially available collagen fleece.",
"name": "BM-MSCs/fibrin glue/collagen fleece",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"... | [
{
"design_group_description": "Group A (BM-MSCs/fibrin glue/collagen fleece) will receive regenerative treatment using autologous bone marrow mesenchymal stem cells free of animal derived reagents, produced in clean room facilities and seeded into collagen scaffolds enriched with autologous fibrin glue",
"d... | [
"Chronic Periodontitis"
] | [
"Aristotle University of Thessaloniki"
] | [
"University of Glasgow"
] | [
[
{
"name": "Autologous Alveolar Bone-Marrow Derived Mesenchymal Stem Cells(Aristotle University Of Thessaloniki)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "PerioRegen"
}
] |
NCT03493282 | [
{
"id_field": "org_study_id",
"id_value": [
"COG0105"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"RF1AG057553"
]
}
] | https://clinicaltrials.gov/study/NCT03493282 | Effect of CT1812 Treatment on Brain Synaptic Density | Study to Evaluate the Safety and Tolerability of Oral CT1812 in Subjects with Mild to Moderate Alzheimer's Disease. | A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Participants With Mild to Moderate Alzheimer's Disease | [
{
"description": "CT1812",
"name": "Active Treatment- CT1812 100 mg",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "CT1812",
"name": "Active Treatment- CT1812 300 mg",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Dru... | [
{
"design_group_description": "High Dose CT1812",
"design_group_title": "300 mg",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "CT1812",
"intervention_name": ... | [
"Alzheimer Disease"
] | [
"Cognition Therapeutics, Inc."
] | [
"National Institute on Aging"
] | [
[
{
"name": "Zervimesine",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "0eae8a52e88e5a823e52552d2ee05838",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "250e3e258d85a845e89aad9e98d35985",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "SPA... |
NCT00886795 | [
{
"id_field": "org_study_id",
"id_value": [
"Tahoe-001"
]
},
{
"id_field": "acronym",
"id_value": [
"TAHOE"
]
}
] | https://clinicaltrials.gov/study/NCT00886795 | Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy | This study is being done to find out if a drug called Abatacept (Orencia ®) is safe and effective in treating people with chronic urticaria (persistent hives). | A Phase I/II Open-label Study to Evaluate The Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy. | [
{
"description": "4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 week, and 8 weeks.",
"name": "abatacept (Orencia ®)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"orencia"
],
"type": "Drug"
}
] | [
{
"design_group_description": "4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 weeks, and 8 weeks.",
"design_group_title": "Abatacept",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Urticaria"
] | [
"The Johns Hopkins University"
] | [
"Bristol Myers Squibb Co."
] | [
[
{
"name": "阿巴西普",
"lang": "CN"
},
{
"name": "Abatacept",
"lang": "EN"
},
{
"name": "アバタセプト（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "222422a950084dd388e03592a0d20ea8",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "TAHOE"
}
] |
NCT03732274 | [
{
"id_field": "org_study_id",
"id_value": [
"MP-VAC-203"
]
}
] | https://clinicaltrials.gov/study/NCT03732274 | Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC | This is an open -label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib in Combination with durvalumab in patients advanced NSCLC who progressed following platinum-based chemotherapy. | Phase 1b/2a, Open Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib in Combination With Durvalumab in Patients With Advanced Non Small Cell Lung Cancer Who Progressed Following Platinum-based Chemotherapy | [
{
"description": "TEW-7197 will be administered orally for 5 days per week (5D/W) at the same time in the morning and evening (BID) approximately 12 hours apart. Durvalumab will be administered as a dose of 1500 mg every 4weeks.",
"name": "TEW-7197",
"normalized_type": "3d1aa88261d64c038413723970f2b58b"... | [
{
"design_group_description": "TEW-7197 will be administered orally for 5 days per week (5D/W) and Durvalumab administration.",
"design_group_title": "Dose Escalation of TEW-7197",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"interv... | [
"Non-Small Cell Lung Cancer Metastatic"
] | [
"MedPacto, Inc."
] | [
"AstraZeneca PLC"
] | [
[
{
"name": "Vactosertib",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "2324032eae0ea824d05ea2d8e2e5a822",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "a3534543399543450822822928024038",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "pha... |
NCT05518188 | [
{
"id_field": "org_study_id",
"id_value": [
"IND No 028202; Serial No 0000"
]
}
] | https://clinicaltrials.gov/study/NCT05518188 | Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) | MELPIDA is proposed for the treatment of subjects with SPG50 and targets neuronal cells to deliver a fully functional human AP4M1 cDNA copy via intrathecal injection to counter the associated neuronal loss. Outcomes will evaluate the safety and tolerability of a single dose of MELPIDA, which will be measured by the tre... | A Phase 1/2 Open-label Intrathecal Administration of MELPIDA to Determine Its Safety and Efficacy for Patients with Spastic Paraplegia Type 50 (SPG50) Caused by Mutation in the AP4M1 Gene. | [
{
"description": "MELPIDA, a recombinant serotype 9 adeno-associated virus (AAV) encoding a codon-optimized human AP4M1 transgene",
"name": "MELPIDA",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_description": "MELPIDA, a gene therapy product",
"design_group_title": "Treatment Arm",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "MELPIDA, a recombinan... | [
"Spasticity, Muscle",
"Microcephaly",
"Intellectual Deficiency",
"Growth Retardation",
"SPG50",
"Spastic Paraplegia"
] | [
"Elpida Therapeutics"
] | [
"The University of Texas Southwestern Medical Center"
] | [
[
{
"name": "Melpida",
"lang": "EN"
}
]
] | null |
NCT00794417 | [
{
"id_field": "org_study_id",
"id_value": [
"VGFT-ST-0708"
]
},
{
"id_field": "secondary_id",
"id_value": [
"TCD10767"
]
}
] | https://clinicaltrials.gov/study/NCT00794417 | A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma | The purpose of the study was to determine whether the combination of aflibercept, pemetrexed and cisplatin is safe and effective in treating non-small cell lung cancer (NSCLC). | A Phase 1/2 Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Carcinoma | [
{
"description": "Administered in combination with the other two interventions via intravenous infusion.",
"name": "Aflibercept",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Administered in combination with the other two interventions via intrav... | [
{
"design_group_description": "Participants received intravenous infusion of aflibercept 6 mg/kg followed by pemetrexed 500 mg/m^2 and then cisplatin 75 mg/m^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) until disease progression, unacceptable toxicity, withdrawal of consent or if another st... | [
"Advanced Carcinoma",
"Non-small Cell Lung Cancer"
] | [
"Regeneron Pharmaceuticals, Inc."
] | [
"Sanofi"
] | [
[
{
"name": "阿柏西普",
"lang": "CN"
},
{
"name": "Aflibercept",
"lang": "EN"
},
{
"name": "アフリベルセプト（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "培美曲塞二钾",
"lang": "CN"
},
{
"name": "Pemetrexed Dipotassium",
"lang": "EN"
... | null |
NCT02573857 | [
{
"id_field": "org_study_id",
"id_value": [
"QP15C11"
]
},
{
"id_field": "acronym",
"id_value": [
"DSMOZ-2"
]
}
] | https://clinicaltrials.gov/study/NCT02573857 | A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection | Part A<br/>-Cohort 1 DSM265 will be administered as a single dose (400 mg). For cohort 1 only, an additional single dose (400 mg) of DSM265 may be given if gametocytemia develops. Treatment with DSM265 will be given after an overnight fasting period of ≥ 8 hours. If dosing is to occur in the evening, subjects will be r... | A Phase Ib Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection | [
{
"description": "Oral suspension from bulk powder",
"name": "DSM265",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Oral suspension from powder in a bottle",
"name": "OZ439",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"oth... | [
{
"design_group_description": "Cohort 1: the efficacy of a single administration of 400 mg DSM265 for the clearance of asexual blood stages of P. falciparum will be determined. Activity of a second single dose of 400 mg DSM265 against gametocytes will be assessed in this cohort only if sexual stages are identif... | [
"Malaria"
] | [
"MMV Medicines for Malaria Venture"
] | [
"Q-Pharm Pty Ltd.",
"QIMR Berghofer Medical Research Institute",
"Clinical Network Services Pty Ltd."
] | [
[
{
"name": "Artefenomel Mesylate",
"lang": "EN"
}
],
[
{
"name": "DSM-265",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "8e454855aa353535ed5939253282a0d8",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "DSMOZ-2"
}
] |
NCT00667641 | [
{
"id_field": "org_study_id",
"id_value": [
"CDR0000592905"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"P30CA072720"
]
},
{
"id_field": "secondary_id",
"id_value": [
"CINJ-050608"
]
},
{
"id_field":... | https://clinicaltrials.gov/study/NCT00667641 | Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors | RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving paclitaxel together with bortez... | Phase I Study of Paclitaxel (Taxol) and Bortezomib (Velcade) in Patients With Refractory Solid Tumor Malignancies Involving an Activated MAPK Pathway | [
{
"description": "Starting dose level 0.70mg/m2",
"name": "bortezomib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"description": "Starting dose level 40mg/m2",
"name": "paclitaxel",
"normalized_type": "3d1aa88261d... | null | [
"Breast Cancer",
"Colorectal Cancer",
"Head and Neck Cancer",
"Lung Cancer",
"Melanoma (Skin)",
"Ovarian Cancer",
"Pancreatic Cancer",
"Prostate Cancer",
"Unspecified Adult Solid Tumor, Protocol Specific"
] | [
"University of Medicine & Dentistry of New Jersey"
] | [
"National Cancer Institute"
] | [
[
{
"name": "紫杉醇",
"lang": "CN"
},
{
"name": "Paclitaxel",
"lang": "EN"
},
{
"name": "パクリタキセル",
"lang": "JP"
}
],
[
{
"name": "硼替佐米",
"lang": "CN"
},
{
"name": "Bortezomib",
"lang": "EN"
},
{
"name": "ボ... | null |
NCT00019019 | [
{
"id_field": "org_study_id",
"id_value": [
"950015"
]
},
{
"id_field": "secondary_id",
"id_value": [
"95-C-0015"
]
},
{
"id_field": "secondary_id",
"id_value": [
"NCI-CPB-334"
]
},
{
"id_field": "secondary_id",
"id_value": [
"NCI-T94-0... | https://clinicaltrials.gov/study/NCT00019019 | Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.<br/>PURPOSE: This phase I trial is studying the side effects and best dose of carboxyamidotriazole and paclitaxel in treating patients with ad... | A PHASE I STUDY OF THE COMBINATION OF CAI AND PACLITAXEL IN ADULT PATIENTS WITH REFRACTORY CANCERS OR LYMPHOMA | [
{
"name": "carboxyamidotriazole",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "paclitaxel",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Brain and Central Nervous System Tumors",
"Breast Cancer",
"Kidney Cancer",
"Lung Cancer",
"Lymphoma",
"Melanoma (Skin)",
"Ovarian Cancer",
"Small Intestine Cancer",
"Unspecified Adult Solid Tumor, Protocol Specific"
] | [
"National Institutes of Health Clinical Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "紫杉醇",
"lang": "CN"
},
{
"name": "Paclitaxel",
"lang": "EN"
},
{
"name": "パクリタキセル",
"lang": "JP"
}
],
[
{
"name": "羧胺三唑",
"lang": "CN"
},
{
"name": "Carboxyamidotriazole",
"lang": "EN"
}
]
] | null |
NCT02603185 | [
{
"id_field": "org_study_id",
"id_value": [
"Hemay007 AU01"
]
}
] | https://clinicaltrials.gov/study/NCT02603185 | PhaseⅠFirst-in-Human Study of Hemay007 in Healthy Volunteers | This phase I study designed in 3 parts is a randomized, placebo-controlled, sequential ascending-dose study of healthy volunteers. The safety, tolerability and pharmacokinetics of ascending single and multiple dose of Hemay007 will be assessed in Part 1 and Part 3, respectively. Food effect following a single oral dose... | A First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Hemay007 | [
{
"name": "Hemay007",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Part 1: Single ascending dose Group Hemay007 tablets will be taken orally once daily in doses of 0.2g, 0.6g,1.2g, 2g, 3g.<br/>Part 2: Food effect group Hemay007 tablets will be taken orally in single dose with a high-fat, high-calorie meal or at overnight fasting.<br/>Part 3: Mult... | [
"Inflammatory Bowel Disease"
] | [
"Hemay Pharmaceutical Pty Ltd"
] | [
"Tianjin Hemei Biological Technology Co.,Ltd."
] | [
[
{
"name": "Hemay007",
"lang": "EN"
}
]
] | null |
NCT04021563 | [
{
"id_field": "org_study_id",
"id_value": [
"SR419-101"
]
}
] | https://clinicaltrials.gov/study/NCT04021563 | The Safety, Tolerability, Pharmacokinetics(PK) of SR419 in Healthy Volunteers | This study is to evaluate the safety, tolerability, PK of SR419 in healthy volunteers. | A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics of SR419 in Healthy Volunteers | [
{
"description": "Ascending single and multiple doses of SR419 orally",
"name": "SR419",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Ascending single and multiple doses of placebo orally",
"name": "Placebo",
"normalized_type": "3d1aa8826... | [
{
"design_group_description": "Ascending single and multiple doses of SR419 orally",
"design_group_title": "SR419",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Ascending... | [
"Healthy Volunteers"
] | [
"Shanghai SIMR Biotech Co., Ltd."
] | [
"Syneos Health, Inc."
] | [
[
{
"name": "SR-419",
"lang": "EN"
}
]
] | null |
NCT01853631 | [
{
"id_field": "org_study_id",
"id_value": [
"H-31970 SAGAN"
]
},
{
"id_domain": "Baylor College of Medicine",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"SAGAN"
]
},
{
"id_field": "acronym",
"id_value": [
"SAGAN"
]
... | https://clinicaltrials.gov/study/NCT01853631 | Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) | Subjects on this study have a type of lymph gland cancer called Non-Hodgkin Lymphoma, acute lymphocytic leukemia, or chronic Lymphocytic Leukemia (these diseases will be referred to as "lymphoma" or "leukemia"). The lymphoma or leukemia has come back or has not gone away after treatment.<br/>The body has different ways... | Phase I Study of Activated T-Cells Expressing Second or Third Generation CD19-Specific Chimeric Antigen Receptors for Advanced B-Cell Non-Hodgkin's Lymphoma, Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia (SAGAN) | [
{
"description": "Three dose levels will be evaluated.<br/>Group 1: CD19.CAR/28137ζ at 1×10^6 cells/m^2 and CD19.CAR/28ζ at 1×10^6 cells/m^2<br/>Group 2: CD19.CAR/28137ζ at 5×10^6 cells/m^2 and CD19.CAR/28ζ at 5×10^6 cells/m^2<br/>Group 3: CD19.CAR/28137ζ at 2×10^7 cells/m^2 and CD19.CAR/28ζ at 2×10^7 cells/m^2... | [
{
"design_group_description": "Each patient will receive a dose of CD19 CAR T Cells administered as an infusion. Each infusion will consist of CD19.CAR/28 T cells and CD19.CAR/28137 T cells.",
"design_group_title": "Dose Escalation: CD19 CAR T Cells for B-cell ALL",
"design_group_type": "Experimental",
... | [
"Non-Hodgkin Lymphoma",
"Chronic Lymphocytic Leukemia",
"Acute Lymphocytic Leukemia"
] | [
"Baylor College of Medicine"
] | [
"Center For Cell & Gene Therapy",
"The Methodist Hospital Research Institute"
] | [
[
{
"name": "Virus-specific-CD19.CAR(Baylor College of Medicine)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "SAGAN"
}
] |
NCT06480201 | [
{
"id_field": "org_study_id",
"id_value": [
"H-54099"
]
}
] | https://clinicaltrials.gov/study/NCT06480201 | Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression | The core objective of this study is to enhance the translational potential of this electroencephalogram (EEG) biomarker by using ketamine(KET)-induced gamma potentiation as a prognostic marker of 4-week treatment outcome. Previous research focused exclusively on KET-induced gamma band potentiation (GBP) in the context ... | Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression | [
{
"description": "Ketamine infusion amount is dictated by BMI, sex, and age.",
"name": "Ketamine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Saline infusion amount is dictated by BMI, sex, and age.",
"name": "Saline",
"normalized_type"... | [
{
"design_group_description": "Healthy controls will receive one saline and ketamine infusion.",
"design_group_title": "Healthy Controls",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervent... | [
"Healthy",
"Major Depressive Disorder",
"Treatment Resistant Depression"
] | [
"Texas A&M University"
] | [
"National Institute of Mental Health"
] | [
[
{
"name": "盐酸氯胺酮",
"lang": "CN"
},
{
"name": "Ketamine Hydrochloride",
"lang": "EN"
},
{
"name": "ケタミン塩酸塩",
"lang": "JP"
}
]
] | null |
NCT02234921 | [
{
"id_field": "org_study_id",
"id_value": [
"14-116B"
]
},
{
"id_field": "acronym",
"id_value": [
"DRibble"
]
}
] | https://clinicaltrials.gov/study/NCT02234921 | Pilot Study of DRibble Vaccine for Prostate Cancer Patients | This is a pilot study of the DRibble vaccine in patients with advanced prostate cancer. | A Pilot Study of DPV-001 DRibble Vaccine With Imiquimod in Advanced Prostate Cancer | [
{
"description": "A single dose of cyclophosphamide, 300 mg/m2, will be administered intravenously 3 Days prior to the first vaccine.",
"name": "Cyclophosphamide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Cytoxan"
],
"type": "Drug"
},
{
"descripti... | [
{
"design_group_description": "Patients will receive cyclophosphamide 3 days prior to the first of 9 planned DRibble vaccine injections. Imiquimod will be applied following 6 injections. Patients will receive 2 HPV vaccinations (Human papillomavirus).",
"design_group_title": "DRibble Vaccine",
"design_g... | [
"Adenocarcinoma of the Prostate"
] | [
"UbiVac, Inc."
] | [
"Earle Chiles Research Institute",
"Providence Cancer Center",
"Providence Health & Services"
] | [
[
{
"name": "环磷酰胺",
"lang": "CN"
},
{
"name": "Cyclophosphamide",
"lang": "EN"
},
{
"name": "シクロホスファミド水和物",
"lang": "JP"
}
],
[
{
"name": "咪喹莫特",
"lang": "CN"
},
{
"name": "Imiquimod",
"lang": "EN"
},
{
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "DRibble"
}
] |
NCT02758730 | [
{
"id_field": "org_study_id",
"id_value": [
"AFF010"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2016-001462-28"
]
}
] | https://clinicaltrials.gov/study/NCT02758730 | Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients | This is a randomized, placebo-controlled, parallel group, patient-blind, single-center phase I clinical trial of repeated once every 4 weeks administration by subcutaneous injection of AFFITOPE® PD01A, adsorbed to aluminium oxide in 30 patients with PD-GBA over a treatment period of 8 weeks. Patients will be randomized... | A Randomized, Placebo-controlled, Parallel Group, Patient-blind, Single-center Phase I Pilot Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A, a New Vaccine Against Alpha-synuclein, in Patients With PD-GBA | [
{
"description": "s.c. injection",
"name": "AFFITOPE® PD01A + Adjuvant",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "s.c. injection",
"name": "Adjuvant without active component",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af... | [
{
"design_group_description": "3 injections of 75µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks",
"design_group_title": "AFFITOPE® PD01A + Adjuvant",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Parkinson's Disease"
] | [
"AFFiRiS AG"
] | [
"University Hospital Tübingen"
] | [
[
{
"name": "Affitope-PD01",
"lang": "EN"
}
]
] | null |
NCT03059563 | [
{
"id_field": "org_study_id",
"id_value": [
"17-000445"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1R21DA042347-01A1"
]
}
] | https://clinicaltrials.gov/study/NCT03059563 | Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users | While deficits in dopamine D2-type receptor availability have been linked to substance use disorders, higher availability associates with better behavioral treatment outcomes for stimulant dependence and resilience to addiction. Varenicline has been shown to upregulate D2-type receptors in drug-naive rats, and could be... | Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users | [
{
"description": "Varenicline is an FDA-approved medication to facilitate smoking cessation. it is also a promising candidate to enhance dopamine signaling by upregulating dopamine D2/D3 (type 2) receptors in the striatum and improve cognitive function.",
"name": "Varenicline",
"normalized_type": "3d1aa... | [
{
"design_group_description": "A standard dose titration regimen that is used for smoking-cessation will be followed. The pharmacist will prepare capsules of varenicline for each week of study participation. Under observation by a study clinician, participants will receive one capsule containing 0.5 mg VAR each... | [
"Dopamine D2/3 Receptor Availability",
"Cognitive Function",
"Methamphetamine Abuse"
] | [
"University of California, Los Angeles"
] | [
"National Institute on Drug Abuse"
] | [
[
{
"name": "酒石酸伐尼克兰",
"lang": "CN"
},
{
"name": "Varenicline Tartrate",
"lang": "EN"
},
{
"name": "バレニクリン酒石酸塩",
"lang": "JP"
}
]
] | null |
NCT07122453 | [
{
"id_field": "org_study_id",
"id_value": [
"CNTX-3001it-LBP-101"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1UG3NS123965-01"
]
}
] | https://clinicaltrials.gov/study/NCT07122453 | Safety and PK of Intrathecal CNTX-3001 for Intractable Chronic Low Back Pain | This clinical study is being conducted to evaluate the safety, tolerability, plasma pharmacokinetics and efficacy of an investigational drug called CNTX-3001. This Phase 1 study is the first time that CNTX-3001 will be given to people (first-in-human study). The study is being done to evaluate whether CNTX-3001, given ... | A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Single Ascending Doses of Intrathecal CNTX-3001 in Subjects With Intractable Chronic Moderate to Severe Low Back Pain | [
{
"description": "non-opioid analgesic",
"name": "CNTX-3001",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Placebo product",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Single intrathecal injection of CNTX-3001",
"design_group_title": "CNTX-3001",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "non-opioid anal... | [
"Lower Back Pain"
] | [
"Centrexion Therapeutics Corp."
] | [
"National Institute of Neurological Disorders & Stroke"
] | [
[
{
"name": "CNTX-3001",
"lang": "EN"
}
]
] | null |
NCT04395950 | [
{
"id_field": "org_study_id",
"id_value": [
"AAAS9106"
]
}
] | https://clinicaltrials.gov/study/NCT04395950 | Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism | The purpose of this study is to assess the effects of an investigational drug, PF-05221304 (PF'1304) on the way the liver handles fat. The planned study will identify why the fat in the blood increases at the same time this drug reduces fat in the liver. The study will have two treatment periods of 6 weeks each, separa... | A Phase 1B, Single-Blinded, Linear Two Period, Placebo-controlled Study to Evaluate the Effects of 10 mg/Day of PF-05221304, Liver Targeted Acetyl-CoA Carboxylase Inhibitor (ACCi) on Very Low Density Lipoprotein ApoB100 and TG Secretion | [
{
"description": "PF-05221304 10 mg daily (two 5mg tablets daily in the morning for 6 weeks)",
"name": "PF-05221304",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"PF1304"
],
"type": "Drug"
},
{
"description": "Placebo two tablets daily in the morning ... | [
{
"design_group_description": "PF-05221304 10 mg daily (two 5mg tablets daily in the morning).",
"design_group_title": "PF-0522130",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_de... | [
"NASH (Nonalcoholic Steatohepatitis)",
"NAFLD (Nonalcoholic Fatty Liver Disease)"
] | [
"Columbia University"
] | [
"Pfizer Inc."
] | [
[
{
"name": "Clesacostat",
"lang": "EN"
}
]
] | null |
NCT06302426 | [
{
"id_field": "org_study_id",
"id_value": [
"INI-4001-101"
]
},
{
"id_field": "secondary_id",
"id_value": [
"INI-4001-101"
]
}
] | https://clinicaltrials.gov/study/NCT06302426 | Trial of INI-4001 in Patients With Advanced Solid Tumours | Phase 1 open-label, dose-escalation and dose-expansion study of INI-4001 as a single agent and in combination with approved checkpoint inhibitors in subjects with advanced solid tumors. | An Open-label, Multiple-Ascending Dose, Two-Part Dose Ranging and Cohort Expansion Study of INI-4001 in Patients With Advanced Solid Tumours | [
{
"description": "INI-4001 is a small molecule TLR7/8 agonist being developed as a standalone treatment for the induction of anti-tumour immune responses and sensitization to immune checkpoint inhibitor (ICI) therapy.",
"name": "INI-4001",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type... | [
{
"design_group_description": "For dose-level 1, INI-4001 will be administered intravenously once per week on Days 1, 8 and 15 of a 21-day cycle. A complementary therapy may be introduced in combination with INI-4001.",
"design_group_title": "INI-4001 Monotherapy Dose Escalation - INI-4001 Dose Level 1",
... | [
"Advanced Solid Tumor"
] | [
"Inimmune Corp."
] | [
"Avance Clinical Pty Ltd."
] | [
[
{
"name": "INI-4001",
"lang": "EN"
}
],
[
{
"name": "纳武利尤单抗",
"lang": "CN"
},
{
"name": "Nivolumab",
"lang": "EN"
},
{
"name": "ニボルマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "阿维单抗",
"lang": "CN"
},
{
... | null |
NCT00509613 | [
{
"id_field": "org_study_id",
"id_value": [
"UMCNONCO 2006_01"
]
},
{
"id_field": "secondary_id",
"id_value": [
"2006-006454-10"
]
}
] | https://clinicaltrials.gov/study/NCT00509613 | Phase 1 Study With Sorafenib and Sirolimus | The purpose of the trial is to identify the recommended dose of sorafenib and sirolimus for combination therapy in subsequent phase 2 trials. | Phase 1 Dose Escalation Study With Sorafenib in Combination With Sirolimus in Patients With Solid Tumor | [
{
"name": "Sorafenib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "Sirolimus",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Advanced Solid Tumor",
"Refractory to Standard Therapies"
] | [
"Radboud University Medical Center"
] | [
"Bayer AG"
] | [
[
{
"name": "西罗莫司",
"lang": "CN"
},
{
"name": "Sirolimus",
"lang": "EN"
},
{
"name": "シロリムス",
"lang": "JP"
}
],
[
{
"name": "甲苯磺酸索拉非尼",
"lang": "CN"
},
{
"name": "Sorafenib Tosylate",
"lang": "EN"
},
{
... | null |
NCT02502006 | [
{
"id_field": "org_study_id",
"id_value": [
"820715"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"5U54HL117798"
]
}
] | https://clinicaltrials.gov/study/NCT02502006 | Variability in Response to Non-steroidal Anti-inflammatory Drugs | This research study will evaluate inter-individual variability in the response to the non-steroidal anti-inflammatory drugs (NSAIDs), celecoxib and naproxen, among healthy adults. It will also investigate what factors, like age, sex, or genetic background, cause this variability. | A Double-blind, Placebo-controlled Investigation of Inter-individual Variability in Pharmacologic Response to Non-steroidal Anti-inflammatory Drugs | [
{
"name": "Celecoxib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Celebrex"
],
"type": "Drug"
},
{
"name": "Naproxen",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Naprosyn"
],
"type": "Drug"
},
{
... | [
{
"design_group_description": "During each treatment phase, subjects will receive celecoxib (200 mg by mouth twice daily), naproxen (500 mg by mouth twice daily), or placebo (twice daily) for 7 days. Subjects will be instructed to take the study medications twice a day (at approximately 8 AM and 8 PM) on an emp... | [
"Healthy"
] | [
"University of Pennsylvania"
] | [
"National Heart, Lung & Blood Institute"
] | [
[
{
"name": "萘普生",
"lang": "CN"
},
{
"name": "Naproxen",
"lang": "EN"
},
{
"name": "ナプロキセン",
"lang": "JP"
}
],
[
{
"name": "塞来昔布",
"lang": "CN"
},
{
"name": "Celecoxib",
"lang": "EN"
},
{
"name": "セレコキシ... | null |
NCT02281344 | [
{
"id_field": "org_study_id",
"id_value": [
"QP14C11"
]
}
] | https://clinicaltrials.gov/study/NCT02281344 | MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants | A single-centre, open-label, study using induced blood stage malaria infection to characterize the activity of MMV390048 against early Plasmodium falciparum blood stage infection. | A Proof-of-concept Study to Assess the Effect of MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants. | [
{
"description": "Supplied as a powder to be prepared as a suspension for oral use",
"name": "MMV390048 20mg",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Cohort 1 will receive a single dose of 20mg MMV390048.",
"design_group_title": "Cohort 1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Sup... | [
"Malaria, Falciparum"
] | [
"MMV Medicines for Malaria Venture"
] | [
"Q-Pharm Pty Ltd."
] | [
[
{
"name": "MMV-390048",
"lang": "EN"
}
]
] | null |
NCT07544589 | [
{
"id_field": "org_study_id",
"id_value": [
"DISP-10-101"
]
}
] | https://clinicaltrials.gov/study/NCT07544589 | A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers | This is a Phase 1, multicenter, open-label study of DISP-10, a combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel (ide-cel, BCMA-directed chimeric antigen receptor [CAR] T), in adult participants with advanced gastrointestinal (GI) cancers.<br/>The study will consist of 2 parts: dose-escala... | A Phase 1 Study to Evaluate the Safety and Efficacy of DISP-10 in Participants With Advanced Gastrointestinal Cancers | [
{
"description": "Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce ide-cel.<br/>During ide-cel production, participants may receive bridging therapy for disease control per Investigator discretion.<br/>DV-10 administration will be followed by lymphodepleti... | [
{
"design_group_description": "Participants will receive DV-10 in combination with ide-cel. Lymphodepleting chemotherapy (fludarabine and cyclophosphamide) will be administered a few days prior to ide-cel.",
"design_group_title": "DISP-10",
"design_group_type": "Experimental",
"design_group_type_nor... | [
"Colorectal Cancer",
"Gastric Adenocarcinoma",
"Esophageal Adenocarcinoma",
"Gastroesophageal Adenocarcinoma"
] | [
"Dispatch Biotherapeutics"
] | [
"Bristol Myers Squibb Co."
] | [
[
{
"name": "DISP-10",
"lang": "EN"
}
]
] | null |
NCT03465436 | [
{
"id_field": "org_study_id",
"id_value": [
"16900"
]
},
{
"id_domain": "Eli Lilly and Company",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"H8H-CD-LAHP"
]
},
{
"id_domain": "CoLucid Pharmaceuticals",
"id_field": "secondary_id... | https://clinicaltrials.gov/study/NCT03465436 | A Study of Lasmiditan on the Heart in Healthy Participants | The purpose of this study was to determine how two doses of lasmiditan affected the heart in healthy participants. The study also evaluated how much lasmiditan got into the blood stream and how long it took the body to get rid of it. Information about side effects was collected. The study lasted a maximum of 46 days fo... | A Randomized, Double-blind, Placebo-controlled, 4-way Crossover Study to Compare the Effects on the Cardiac De- and Repolarization Duration as Well as Other Cardiac Safety Parameters of Two Doses of Oral Lasmiditan (100 mg and 400 mg) With Those of Moxifloxacin (400 mg) and Placebo in Healthy Subjects | [
{
"description": "100 mg administered orally (PO)",
"name": "Lasmiditan",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"LY573144"
],
"type": "Drug"
},
{
"description": "400 mg administered PO",
"name": "Lasmiditan",
"normalized_type": "3d1aa882... | [
{
"design_group_description": "A single, PO dose of 100 mg lasmiditan administered on Day 1 in one of four treatment periods.",
"design_group_title": "100 milligrams (mg) Lasmiditan",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"int... | [
"Healthy"
] | [
"Eli Lilly & Co."
] | [
"CoLucid Pharmaceuticals, Inc."
] | [
[
{
"name": "拉米地坦",
"lang": "CN"
},
{
"name": "Lasmiditan Succinate",
"lang": "EN"
},
{
"name": "ラスミジタンコハク酸塩",
"lang": "JP"
}
]
] | null |
NCT00423865 | [
{
"id_field": "org_study_id",
"id_value": [
"MSKCC 06-129"
]
},
{
"id_field": "secondary_id",
"id_value": [
"MSKCC-06129"
]
},
{
"id_field": "nct_alias",
"id_value": [
"NCT00406666"
]
}
] | https://clinicaltrials.gov/study/NCT00423865 | Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors | RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Everolimus may also help cisplatin work... | A Phase I Study of Weekly Low-Dose Cisplatin Plus Escalating Doses of Oral RAD001(Everolimus) for Patients With Advanced Solid Tumors | [
{
"description": "cisplatin (20 mg/m2 intravenously on Days 1, 8, and 15)",
"name": "cisplatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "escalating doses of daily RAD001 tablets (per oral or via percutaneous gastrostomy tube, Days 1 -21 of a... | [
{
"design_group_description": "This will be a single institution phase I study of low dose weekly cisplatin (20 mg/m2 intravenously on Days 1, 8, and 15) plus escalating doses of daily RAD001 tablets (per oral or via percutaneous gastrostomy tube, Days 1 -21 of a 28-Day Cycle) for patients with advanced solid t... | [
"Unspecified Adult Solid Tumor, Protocol Specific"
] | [
"Memorial Sloan Kettering Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "顺铂",
"lang": "CN"
},
{
"name": "Cisplatin",
"lang": "EN"
},
{
"name": "シスプラチン",
"lang": "JP"
}
],
[
{
"name": "依维莫司",
"lang": "CN"
},
{
"name": "Everolimus",
"lang": "EN"
},
{
"name": "エベロリ... | null |
NCT04044001 | [
{
"id_field": "org_study_id",
"id_value": [
"PanACEA-BTZ-043-02"
]
}
] | https://clinicaltrials.gov/study/NCT04044001 | BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA) | This is a prospective, open label, two-centre, randomized, controlled, two-stage, phase Ib/IIa study to evaluate the safety, tolerability, PK, drug-drug interaction and bactericidal activity of BTZ-043 administered orally once daily over 14 days to participants with newly diagnosed, uncomplicated, smear-positive, drug-... | A Prospective Phase Ib/IIa, Active-controlled, Randomized, Open-label Study to Evaluate the Safety, Tolerability, Extended Early Bactericidal Activity and Pharmacokinetics of Multiple Oral Doses of BTZ-043 Tablets in Subjects With Newly Diagnosed, Uncomplicated, Smear-positive, Drug-susceptible Pulmonary Tuberculosis | [
{
"description": "BTZ-043 (250mg per tablet)",
"name": "BTZ-043",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Rifafour e-275® (150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide, 275 mg ethambutol per tablet)",
"name": "Rifafour e-275®",
... | [
{
"design_group_description": "Patients will receive 1 tablet of BTZ-043 orally once daily, containing 250mg BTZ-043 from Day 1 through to Day 14",
"design_group_title": "Stage 1 - Cohort 1 (BTZ 250)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22c... | [
"Pulmonary Tuberculoses",
"Other Specified Pulmonary Tuberculosis"
] | [
"Ludwig-Maximilians-Universität München"
] | [
"Radboud University Medical Center",
"German Federal Ministry Of Education And Research"
] | [
[
{
"name": "多替拉韦钠",
"lang": "CN"
},
{
"name": "Dolutegravir Sodium",
"lang": "EN"
},
{
"name": "ドルテグラビルナトリウム",
"lang": "JP"
}
],
[
{
"name": "BTZ-043",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "8a0a8094422244225a055e053258e25a",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "PanACEA-BTZ-043-02"
}
] |
NCT01274182 | [
{
"id_field": "org_study_id",
"id_value": [
"GP13-201"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2010-021184-32"
]
},
{
"id_domain": "Novartis",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value":... | https://clinicaltrials.gov/study/NCT01274182 | GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy | The purpose of this study is to determine the PK/PD, efficacy and safety of GP2013 in patients with severe rheumatoid arthritis. | A Randomized, Double-blind, Controlled Study to Evaluate PK, PD, Safety and Efficacy of GP2013 and Rituximab in Patients With Rheumatoid Arthritis Refractory or Intolerant to Standard DMARDs and up to Three Anti-TNF Therapies. | [
{
"description": "1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)",
"name": "GP2013",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "1000 mg iv infusion on two separate occasions, two weeks apart (... | [
{
"design_group_title": "GP2013",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)",
... | [
"Rheumatoid Arthritis"
] | [
"Sandoz Group AG"
] | [
"Novartis Pharmaceuticals Corp."
] | [
[
{
"name": "利妥昔单抗生物类似药(Sandoz International GmbH)",
"lang": "CN"
},
{
"name": "Rituximab(Sandoz International GmbH)",
"lang": "EN"
},
{
"name": "リツキシマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT03576547 | [
{
"id_field": "org_study_id",
"id_value": [
"2017-0313"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2018-01100"
]
},
{
"id_domain": "M D Anderson Cancer Center"... | https://clinicaltrials.gov/study/NCT03576547 | Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia | This phase I/II trial studies the best dose of venetoclax when given together with ponatinib and dexamethasone and to see how well they work in treating participants with Philadelphia chromosome or BCR-ABL positive acute lymphoblastic leukemia or chronic myelogenous leukemia that has come back or does not respond to tr... | A Phase I/II Study of the Combination of Venetoclax, Ponatinib and Corticosteroids in Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Lymphoid Blast Phase Chronic Myelogenous Leukemia | [
{
"description": "Given PO or IV",
"name": "Dexamethasone",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Aacidexam",
"Adexone",
"Aknichthol Dexa",
"Alba-Dex",
"Alin",
"Alin Depot",
"Alin Oftalmico",
"Amplidermis",
"Anem... | [
{
"design_group_description": "The regimen consists of 4 cycles of induction/consolidation followed by up to 2 years of maintenance therapy for responding patients.",
"design_group_title": "Phase I (400 mg Ponatinib) Treatment (ponatinib, venetoclax, dexamethasone, rituximab)",
"design_group_type": "Exp... | [
"Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
"Philadelphia Chromosome Positive",
"Recurrent Acute Lymphoblastic Leukemia",
"Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
"Refractory Acute Lymphoblastic Leukemia",
"Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive",... | [
"The University of Texas MD Anderson Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "维奈克拉",
"lang": "CN"
},
{
"name": "Venetoclax",
"lang": "EN"
},
{
"name": "ベネトクラクス",
"lang": "JP"
}
],
[
{
"name": "地塞米松磷酸钠",
"lang": "CN"
},
{
"name": "Dexamethasone Sodium Phosphate",
"lang": "EN"
}... | null |
NCT01755975 | [
{
"id_field": "org_study_id",
"id_value": [
"12-170"
]
}
] | https://clinicaltrials.gov/study/NCT01755975 | Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma | The treatments used to treat lymphoma and multiple myeloma sometimes do not always work well or they may only work for a short period of time. This is why new treatments are being tested.<br/>This study will test a new combination of two drugs that are already approved by the Food and Drug Administration for treatment ... | A Phase Ib/IIa Study of Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma | [
{
"description": "Romidepsin will be administered intravenously on days 1, 8, and 15 of a 28-day cycle.",
"name": "Romidepsin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Lenalidomide will be taken orally daily for 21 days of a 28-day cycle.",
... | [
{
"design_group_description": "This will be a multicentered, open label, phase Ib/IIa trial of romidepsin and lenalidomide in patients with relapsed or refractory lymphomas or multiple myeloma. Lenalidomide will be provided in accordance with the Celgene Corporation's Revlimid REMS® program. Per standard Revlim... | [
"Multiple Myeloma",
"Non-Hodgkin's Lymphoma"
] | [
"Memorial Sloan Kettering Cancer Center"
] | [
"Weill Medical College of Cornell University",
"University of Nebraska",
"Celgene Corp.",
"Biologics, Inc.",
"St. Francis Hospital & Medical Center"
] | [
[
{
"name": "来那度胺",
"lang": "CN"
},
{
"name": "Lenalidomide",
"lang": "EN"
},
{
"name": "レナリドミド水和物",
"lang": "JP"
}
],
[
{
"name": "罗米地辛",
"lang": "CN"
},
{
"name": "Romidepsin",
"lang": "EN"
},
{
"name... | null |
NCT05672095 | [
{
"id_field": "org_study_id",
"id_value": [
"23231"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2022-10203"
]
},
{
"id_domain": "City of Hope Medical enter",
... | https://clinicaltrials.gov/study/NCT05672095 | Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer | This phase I/II trial tests the safety, side effects and best dose of a combination therapy (niraparib and selenium) in treating patients with BRCA negative ovarian cancer that has come back (recurrent) and does not respond to platinum based therapy (platinum resistant). Selenium is a form of the trace element with pot... | Phase I/II Trial of Niraparib/Selenium Combination Treatment in Patients With BRCA1/2-Wild Type Recurrent Platinum-Resistant Ovarian Cancer | [
{
"description": "Undergo needle or core biopsy",
"name": "Biopsy",
"normalized_type": "a49da0f516744e0f8a08ffdea4946e99",
"other_name": [
"BIOPSY_TYPE",
"Bx"
],
"type": "Procedure"
},
{
"description": "Undergo blood sample collection",
"name": "Biospecimen Collection... | [
{
"design_group_description": "Patients receive selenium IV and niraparib PO on study. Patients also undergo CT, MRI, biopsy, and collection of blood samples throughout the trial.",
"design_group_title": "Treatment (selenium, niraparib)",
"design_group_type": "Experimental",
"design_group_type_norma... | [
"Platinum-Resistant Fallopian Tube Carcinoma",
"Platinum-Resistant Ovarian Carcinoma",
"Platinum-Resistant Primary Peritoneal Carcinoma",
"Recurrent Fallopian Tube Carcinoma",
"Recurrent Ovarian Carcinoma",
"Recurrent Primary Peritoneal Carcinoma"
] | [
"City of Hope National Medical Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "Selenium",
"lang": "EN"
}
],
[
{
"name": "甲苯磺酸尼拉帕利",
"lang": "CN"
},
{
"name": "Niraparib Tosylate",
"lang": "EN"
},
{
"name": "ニラパリブトシル酸塩水和物",
"lang": "JP"
}
]
] | null |
NCT04123470 | [
{
"id_field": "org_study_id",
"id_value": [
"LOKON003"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2019-003300-12"
]
}
] | https://clinicaltrials.gov/study/NCT04123470 | A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma | This study aims to evaluate safety and effect of combining an oncolytic adenovirus (delolimogene mupadenorepvec; LOAd703) with atezolizumab in patients with melanoma. LOAd703 will be administered intratumorally for up to 12 injections while atezolizumab will be administered intravenously for the duration of the active ... | A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma | [
{
"description": "LOAd703 is an oncolytic adenovirus encoding TMZ-CD40L and 4-1BBL",
"name": "delolimogene mupadenorepvec",
"normalized_type": "288887f0545745558ff1ab1c85757552",
"other_name": [
"LOAd703"
],
"type": "Genetic"
},
{
"description": "Atezolizumab is an anti-PD-L1 a... | [
{
"design_group_description": "Delolimogene mupadenorepvec plus atezolizumab",
"design_group_title": "Treatment",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Atezolizuma... | [
"Malignant Melanoma"
] | [
"Lokon Pharma AB"
] | [
"Precision Oncology LLC"
] | [
[
{
"name": "阿替利珠单抗",
"lang": "CN"
},
{
"name": "Atezolizumab",
"lang": "EN"
},
{
"name": "アテゾリズマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "Delolimogene mupadenorepvec",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "3254a9e289d258e3ad2eea8aeda382a9",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "a8248392552d025a202d5a239e5a898a",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "LOK... |
NCT06780111 | [
{
"id_field": "org_study_id",
"id_value": [
"3475-06E"
]
},
{
"id_domain": "MSD",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"MK-3475-06E"
]
},
{
"id_domain": "EU CT",
"id_field": "secondary_id",
"id_type": "Registry Ident... | https://clinicaltrials.gov/study/NCT06780111 | Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) | Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC). ESCC is a type of cancer that starts in certain cells that line the esophagus. The esophagus is the tube that connects the throat to the stomach. This study will look at ESCC that is either locally advanced unresectable, which mean... | A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E | [
{
"description": "IV infusion",
"name": "Pembrolizumab",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"KEYTRUDA®",
"MK-3475"
],
"type": "Biological"
},
{
"description": "IV infusion",
"name": "I-DXd",
"normalized_type": "30faef638ae74cc79... | [
{
"design_group_description": "Participants will receive 400 mg of pembrolizumab via intravenous (IV) infusion every six weeks (Q6W) on Day 1 of each 42 day cycle up to 18 cycles (up to approximately 2 years), and mFOLFOX6 chemotherapy: oxaliplatin 85 mg/m^2 via IV infusion every 2 weeks (Q2W) until progressive... | [
"Esophageal Squamous Cell Carcinoma"
] | [
"Merck Sharp & Dohme LLC"
] | [
"Daiichi Sankyo Co., Ltd."
] | [
[
{
"name": "亚叶酸钙",
"lang": "CN"
},
{
"name": "Leucovorin Calcium",
"lang": "EN"
},
{
"name": "ホリナートカルシウム",
"lang": "JP"
}
],
[
{
"name": "Ifinatamab deruxtecan",
"lang": "EN"
},
{
"name": "イフィナタマブ デルクステカン（遺伝子組換え）",
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "MK-3475-06E"
}
] |
NCT03423342 | [
{
"id_field": "org_study_id",
"id_value": [
"STUDY00001830"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1R21HL126209-01"
]
}
] | https://clinicaltrials.gov/study/NCT03423342 | Nicotinamide Riboside in Systolic Heart Failure | Mitochondrial dysfunction has been implicated in heart failure (HF), and is associated with an imbalance in intracellular ratio of reduced nicotinamide-adenine dinucleotide (NADH) to oxidized nicotinamide-adenine dinucleotide (NAD), or the NADH/NAD ratio. In mouse models of HF, we have found that normalization of the N... | Safety and Tolerability of the Nutritional Supplement, Nicotinamide Riboside, in Systolic Heart Failure | [
{
"description": "nicotinamide riboside capsule",
"name": "nicotinamide riboside",
"normalized_type": "98bb1fc78f3d456a8b67c466ae710699",
"other_name": [
"Niagen"
],
"type": "Dietary Supplement"
},
{
"description": "matching placebo capsule",
"name": "Placebo",
"normali... | [
{
"design_group_description": "Nicotinamide riboside will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be cont... | [
"Heart Failure, Systolic"
] | [
"University of Washington"
] | [
"National Heart, Lung & Blood Institute"
] | [
[
{
"name": "烟酰胺核糖",
"lang": "CN"
},
{
"name": "Nicotinamide riboside",
"lang": "EN"
}
]
] | null |
NCT04776239 | [
{
"id_field": "org_study_id",
"id_value": [
"20200874"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1R01HL134558-01"
]
},
{
"id_field": "acronym",
"id_value": [
"ACESO-IHD"
]
}
] | https://clinicaltrials.gov/study/NCT04776239 | Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD) | The purpose of this study is to test the hypothesis that allogeneic Mesenchymal Stem Cells (MSCs) promote systemic and coronary endothelial repair through rescue of bone marrow progenitors in type 2 diabetic patients with symptomatic IHD compared to placebo. | Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. | [
{
"description": "1 single intravenous infusion",
"name": "100 million Allogeneic Mesenchymal Human Stem Cells",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"allo-human Mesenchymal Stem Cells (hMSCs)",
"stem cells"
],
"type": "Drug"
},
{
"descri... | [
{
"design_group_description": "Participants in this group will be receive a single administration of intravenous allogeneic human Mesenchymal Stem Cells (hMSCs) (100 million).",
"design_group_title": "Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group",
"design_group_type": "Experimental",
"des... | [
"Diabetes Mellitus",
"Ischemic Heart Disease"
] | [
"University of Miami"
] | [
"National Heart, Lung & Blood Institute"
] | [
[
{
"name": "Allogeneic human mesenchymal stem cells(University of Miami)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ACESO-IHD"
}
] |
NCT07502768 | [
{
"id_field": "org_study_id",
"id_value": [
"SHCA-NKT-2601"
]
},
{
"id_field": "acronym",
"id_value": [
"EpiRev-NKT"
]
}
] | https://clinicaltrials.gov/study/NCT07502768 | Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma | This is a multicenter, open-label, phase Ib/II study evaluating tislelizumab in combination with zeprumetostat (SHR2554) in patients with relapsed or refractory NK/T-cell lymphoma after at least one prior asparaginase-based chemotherapy-containing regimen, with or without radiotherapy. In phase Ib, two fixed dose level... | A Multicenter, Open-Label, Seamless Phase Ib/II Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Zeprumetostat (SHR2554) in Patients With Relapsed or Refractory NK/T-Cell Lymphoma | [
{
"description": "Tislelizumab 200 mg administered intravenously on day 1 of each 21-day cycle.",
"name": "Tislelizumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Zeprumetostat (SHR2554), an oral EZH2 inhibitor, administered twice daily. In p... | [
{
"design_group_description": "Tislelizumab 200 mg IV every 3 weeks plus zeprumetostat 300 mg orally twice daily.",
"design_group_title": "Phase Ib Dose Level A",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{... | [
"Extranodal NK/T-cell Lymphoma",
"NK/T-cell Lymphoma",
"Relapsed or Refractory NK/T-Cell Lymphoma"
] | [
"Fudan University"
] | [
"Fudan University"
] | [
[
{
"name": "替雷利珠单抗",
"lang": "CN"
},
{
"name": "Tislelizumab",
"lang": "EN"
},
{
"name": "チスレリズマブ（遺伝子組換え）（JAN）",
"lang": "JP"
}
],
[
{
"name": "泽美妥司他",
"lang": "CN"
},
{
"name": "Zeprumetostat",
"lang": "EN"
}
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "EpiRev-NKT"
}
] |
NCT00852124 | [
{
"id_field": "org_study_id",
"id_value": [
"HP-00040151"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1R21AT004089-01A1"
]
}
] | https://clinicaltrials.gov/study/NCT00852124 | Safety of VSL#3 in Adult Asthmatics | We are proposing to test the safety of the probiotic, VSL#3, in a placebo controlled double blind safety study in 30 asthmatic adults. This adult safety trial was requested by the FDA IND review of a pediatric asthma protocol.<br/>Adults with a doctor diagnosis of persistent asthma will take VSL#3 or placebo twice dail... | Safety of VSL#3 for Adult Asthmatics | [
{
"description": "VSL#3 2 times daily",
"name": "VSL#3",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "1 packet 2 x daily of placebo",
"name": "VSL#3 or placebo",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Bi... | [
{
"design_group_description": "Packets similar to VSL#3 will be taken 2 X daily but not containing active bacteria",
"design_group_title": "Placebo",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
... | [
"Asthma"
] | [
"University of Maryland Baltimore"
] | [
"National Center For Complementary & Integrative Health"
] | [
[
{
"name": "Live lactic acid bacteria probiotics(Vsl Pharmaceuticals, Inc.)",
"lang": "EN"
}
]
] | null |
NCT04713488 | [
{
"id_field": "org_study_id",
"id_value": [
"06 - Sputnik Light - 2020"
]
}
] | https://clinicaltrials.gov/study/NCT04713488 | An Open Study on the Safety, Tolerability, and Immunogenicity of "Sputnik Light" Vaccine | Phase I-II open prospective, two-stage, non-randomized study in healthy volunteers. | An Open Study on the Safety, Tolerability, and Immunogenicity of "Sputnik Light" t Vaccine for Prevention of Coronavirus Infection Caused by the SARS-CoV-2 Viruso | [
{
"description": "solution for intramuscular injection Composition for 1 dose (0.5 ml)",
"name": "Sputnik Light",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"vector vaccine to help prevent the SARS-CoV-2-induced coronavirus infection"
],
"type": "Biological"... | [
{
"design_group_description": "solution for intramuscular injection Composition for 1 dose (0.5 ml): Active substance: recombinant serotype 26 adenoviral particles containing the SARS-CoV-2 S protein gene, in the amount of (1.0±0.5) x 10*11 particles per dose.",
"design_group_title": "Sputnik Light Vaccine"... | [
"COVID-19 Prevention"
] | [
"Gamaleya Research Institute Of Epidemiology And Microbiology, Health Ministry Of The Russian Federation"
] | [
"Russian Direct Investment Fund"
] | [
[
{
"name": "Gam-COVID-Vac",
"lang": "EN"
}
]
] | null |
NCT01083667 | [
{
"id_field": "org_study_id",
"id_value": [
"0903010259"
]
}
] | https://clinicaltrials.gov/study/NCT01083667 | SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS) | The objective of this study will be to evaluate the safety, tolerability and effect on SOD1 levels by pyrimethamine in patients with familial amyotrophic lateral sclerosis. | Phase I/II Study of SOD1 Inhibition by Pyrimethamine in Familial ALS | [
{
"description": "Open Label, dose escalating,",
"name": "Pyrimethamine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Daraprim"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Open label. Only one arm will receive the intervention.",
"design_group_title": "Pyrimethamine",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description"... | [
"Familial Amyotrophic Lateral Sclerosis"
] | [
"Weill Medical College of Cornell University"
] | [
"Muscular Dystrophy Association, Inc."
] | [
[
{
"name": "乙胺嘧啶",
"lang": "CN"
},
{
"name": "Pyrimethamine",
"lang": "EN"
}
]
] | null |
NCT05905120 | [
{
"id_field": "org_study_id",
"id_value": [
"SMHC-224"
]
}
] | https://clinicaltrials.gov/study/NCT05905120 | Assessing Dopamine Transporter Occupancy in the Healthy Adult Brain With Toludivenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) | This study was a single-arm, non-randomized, open-label clinical study to assess dopamine transporter occupancy in the brain of healthy adults using 11C-CFT positron emission tomography (PET) | A Single-Arm, Non-Randomized, Open-Label, Exploratory Mechanistic Validation (PoM) Clinical Trial of Toludivenlafaxine Hydrochloride Extended-Release Tablets Assessing Dopamine Transporter Occupancy in the Healthy Adult Brain Using 11C-CFT Positron Emission Tomography (PET) | [
{
"description": "80 mg/tablet, 2 tablets each time, once a day, for 4 days, orally at 30 min after the start of meals, 200 mL water to take",
"name": "Toludivenlafaxine hydrochloride sustained-release tablets",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "80 mg/tablet, 2 tablets each time, once a day, for 4 days",
"design_group_title": "Toludivenlafaxine hydrochloride sustained-release tablets",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention"... | [
"Major Depressive Disorder"
] | [
"Shanghai Mental Health Center"
] | [
"Yantai University"
] | [
[
{
"name": "盐酸托鲁地文拉法辛",
"lang": "CN"
},
{
"name": "Toludesvenlafaxine Hydrochlorid",
"lang": "EN"
}
]
] | null |
NCT00005807 | [
{
"id_field": "org_study_id",
"id_value": [
"CDR0000067800"
]
},
{
"id_field": "secondary_id",
"id_value": [
"AECM-9911378"
]
},
{
"id_field": "secondary_id",
"id_value": [
"NCI-98"
]
},
{
"id_field": "secondary_id",
"id_value": [
"NYU-... | https://clinicaltrials.gov/study/NCT00005807 | Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.<br/>PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have metastatic, recurrent, or locally advanced, ovarian cancer, breast cancer, or metastatic or unresectab... | A Phase I Scientific Exploratory Study of Epothilone B Analog in Patients With Solid Tumors and Gynecological Malignancies | [
{
"description": "anticancer agent for the treatment of patients with malignant tumors.",
"name": "BMS-247550",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"epothilone derivative"
],
"type": "Drug"
}
] | [
{
"design_group_description": "dose escalation treatment",
"design_group_title": "Treated Participants",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "anticancer agent for... | [
"Breast Cancer",
"Ovarian Cancer",
"Unspecified Adult Solid Tumor, Protocol Specific"
] | [
"Albert Einstein College of Medicine, Inc."
] | [
"National Cancer Institute"
] | [
[
{
"name": "伊沙匹隆",
"lang": "CN"
},
{
"name": "Ixabepilone",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "BMS-247550"
}
] |
NCT00942136 | [
{
"id_field": "org_study_id",
"id_value": [
"112941"
]
}
] | https://clinicaltrials.gov/study/NCT00942136 | GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study | GSK1349572 is an integrase inhibitor that is currently being evaluated for the treatment of HIV infection. The primary objective of this study is to determine whether the addition of a proton pump inhibitor, omeprazole, to GSK1349572 impacts the blood levels of GSK1349572. It will also evaluate if a high fat meal impac... | The Official Study Title Exceeds the 300 Character Limit for This Field. See Detailed Study Description Section for Official Study Title. | [
{
"description": "GSK1349572 250 mg suspension as a single dose. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.",
"name": "GSK1349572",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{... | [
{
"design_group_description": "Subjects in Cohort 1, Sequence 1 will receive a single dose of GSK134972 50 mg after a fast of 10 hours in Period 1. Following a 7 day washout, they will receive a single dose of GSK134972 50 mg after a high fat meal in Period 2. After the last PK sample is collected in Period 2, ... | [
"Healthy Volunteer"
] | [
"GSK Plc"
] | [
"Shionogi, Inc."
] | [
[
{
"name": "多替拉韦钠",
"lang": "CN"
},
{
"name": "Dolutegravir Sodium",
"lang": "EN"
},
{
"name": "ドルテグラビルナトリウム",
"lang": "JP"
}
],
[
{
"name": "奥美拉唑",
"lang": "CN"
},
{
"name": "Omeprazole",
"lang": "EN"
},
{
... | null |
NCT07215923 | [
{
"id_field": "org_study_id",
"id_value": [
"ATI-1013-001"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"5U01DA058547-03"
]
}
] | https://clinicaltrials.gov/study/NCT07215923 | A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers | This study is a first-in-human clinical trial of drug ATI-1013, in healthy adult cigarette smokers. The main questions it aims to answer are to learn about the safety of drug ATI-1013, how long drug ATI-1013 remains within the body, does drug ATI-1013 trigger an immune response, and the effects of drug ATI-1013 on nico... | A First in Human, Double-Blind, Placebo-Controlled, Randomized Evaluation of Single Ascending Doses of ATI-1013, a Human Monoclonal Antibody to Nicotine in Healthy Smokers | [
{
"description": "Single intravenous (IV) infusion of ATI-1013, 0.2 g total dose.",
"name": "ATI-1013 (0.2 g)",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "Single IV infusion of ATI-1013, 0.8 g total dose.",
"name": "ATI-1013 (0.8 g)",... | [
{
"design_group_description": "Single-ascending-dose Cohort 1. Participants receive a single intravenous (IV) infusion of ATI-1013 0.2 g on Day 1. Randomization within the cohort is 4:1 (ATI-1013:placebo).",
"design_group_title": "ATI-1013 (0.2 g)",
"design_group_type": "Experimental",
"design_group... | [
"Thromboangiitis Obliterans (Buerger's Disease)"
] | [
"Antidote Therapeutics, Inc."
] | [
"National Institute on Drug Abuse",
"National Institutes of Health"
] | [
[
{
"name": "ATI-1013",
"lang": "EN"
}
]
] | null |
NCT04314206 | [
{
"id_field": "org_study_id",
"id_value": [
"VNRX-5024-101"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"272201600029C-P00007-9999-2"
]
},
{
"id_domain": "DMID",
"id_field": "secondary_id",
"id_type": "Other Ident... | https://clinicaltrials.gov/study/NCT04314206 | VNRX-5024 Safety and PK in Healthy Adult Volunteers | This is a 2-part dose-ranging study to evaluate the safety and pharmacokinetics of escalating doses of VNRX-5024. Subjects will be enrolled in one of three dose cohorts. They will receive a single dose on Day 1 in Part 1 and will proceed into the multiple dose Part 2 of the study after safety assessments and PK samples... | A Randomized, Double-Blind, Placebo-Controlled, Sequential Group, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single and Repeat Doses of VNRX-5024 Administered Orally for 10 Days in Healthy Adult Volunteers | [
{
"description": "Part 1: one dose<br/>Part 2:<br/>Cohort 1: 10 doses (once a day for 10 days) Cohort 2: 19 doses (once every 12 hours [q12h] dosing for 9 days with a single morning dose on Day 10) Cohort 3: 28 doses (once every 8 hours [q8h] dosing for 9 days with a single morning dose on Day 10)",
"name":... | [
{
"design_group_description": "Capsule formulation",
"design_group_title": "VNRX-5024",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Part 1: one dose<br/>Part 2:<br/>Coho... | [
"Healthy Subjects"
] | [
"Basilea Pharmaceutica AG"
] | [
"National Institute of Allergy & Infectious Diseases"
] | [
[
{
"name": "VNRX-5024",
"lang": "EN"
}
]
] | null |
NCT02439788 | [
{
"id_field": "org_study_id",
"id_value": [
"H-33272, GINAKIT"
]
},
{
"id_field": "acronym",
"id_value": [
"GINAKIT"
]
}
] | https://clinicaltrials.gov/study/NCT02439788 | 3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA | This research study is for patients that have a cancer called Neuroblastoma that has either come back after treatment or did not respond to the standard medicines used to treat it. This study combines two different ways of fighting cancer: antibodies and Natural Killer T cells. Antibodies are types of proteins that pro... | 3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND INDUCIBLE CASPASE 9 SAFETY SWITCH TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS TO TREAT CHILDREN WITH NEUROBLASTOMA (GINAKIT) | [
{
"description": "500 mg/m2/day x 2 days; for patients <12 kg the dose is 16.7 mg/kg/day x 2 days; Cyclophospamide will be given daily starting Day -4 prior to administration of GINAKIT cells.",
"name": "cyclophosphamide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
... | [
{
"design_group_description": "Patients receive chemotherapy with Fludarabine and Cyclophosphamide and then an infusion of the GINAKIT cells (iC9-GD2.CD28.OX40.zeta Natural Killer T cells)",
"design_group_title": "GINAKIT Cells plus chemotherapy",
"design_group_type": "Experimental",
"design_group_t... | [
"Neuroblastoma"
] | [
"Baylor College of Medicine"
] | [
"Alex's Lemonade Stand Foundation",
"Center For Cell & Gene Therapy"
] | [
[
{
"name": "磷酸氟达拉滨",
"lang": "CN"
},
{
"name": "Fludarabine Phosphate",
"lang": "EN"
},
{
"name": "フルダラビンリン酸エステル",
"lang": "JP"
}
],
[
{
"name": "GINAKIT-Cells(Baylor College of Medicine)",
"lang": "EN"
}
],
[
{
"name... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "GINAKIT"
}
] |
NCT01036893 | [
{
"id_field": "org_study_id",
"id_value": [
"M0001-C101"
]
}
] | https://clinicaltrials.gov/study/NCT01036893 | M0001 Effects on Oral Contraceptive Plasma Levels | This is a randomized, open-label, two-way cross-over drug-drug interaction Phase I trial.<br/>The objectives of this phase I trial are to investigate in healthy female subjects:<br/>* the effect of prucalopride on the absorption of ethinylestradiol and norethisterone acetate, the active constituents of several oral con... | The Effect of Prucalopride on the Plasma Levels of Oral Contraceptives (Ethinylestradiol and Norethisterone) in Healthy Subjects | [
{
"description": "prucalopride 2 mg oral dosing o.d. for 6 days",
"name": "prucalopride",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_title": "oral contraceptives without prucalopride",
"design_group_type": "No Intervention"
},
{
"design_group_description": "prucalopride",
"design_group_title": "oral contraceptives with prucalopride",
"design_group_type": "Active Comparator",
"design_group_type_normaliz... | [
"Healthy Volunteers"
] | [
"Movetis NV"
] | [
"FOCUS GmbH"
] | [
[
{
"name": "琥珀酸普芦卡必利",
"lang": "CN"
},
{
"name": "Prucalopride Succinate",
"lang": "EN"
}
]
] | null |
NCT05440942 | [
{
"id_field": "org_study_id",
"id_value": [
"20220171"
]
}
] | https://clinicaltrials.gov/study/NCT05440942 | Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma | The purpose of this research is to test whether a combination treatment of Trametinib, Retifanlimab, and Ruxolitinib (TR^2) will reduce tumor size in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). | A Phase 1 Trial of Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma | [
{
"description": "Trametinib will be administered orally once daily via tablet.",
"name": "Trametinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"GSK1120212",
"Mekinist",
"TMT212-NXA"
],
"type": "Drug"
},
{
"description": "Ruxolitinib w... | [
{
"design_group_description": "Participants in this group will receive Trametinib, Ruxolitinib and Retifanlimab in a dose escalation/de-escalation design to determine the maximum tolerated dose (MTD). Participants will receive Trametinib and Ruxolitinib for two weeks on (Days 1-14) and two weeks off (Days 15-28... | [
"Pancreatic Ductal Adenocarcinoma"
] | [
"University of Miami"
] | [
"Novartis Pharmaceuticals Corp.",
"Incyte Corp.",
"University of Miami"
] | [
[
{
"name": "二甲基亚砜曲美替尼",
"lang": "CN"
},
{
"name": "Trametinib dimethyl sulfoxide",
"lang": "EN"
},
{
"name": "トラメチニブ ジメチルスルホキシド付加物",
"lang": "JP"
}
],
[
{
"name": "磷酸芦可替尼",
"lang": "CN"
},
{
"name": "Ruxolitinib Phosphat... | null |
NCT00562250 | [
{
"id_field": "org_study_id",
"id_value": [
"MB102-016"
]
}
] | https://clinicaltrials.gov/study/NCT00562250 | Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects | The purpose of the study is to determine the effect of glimepiride on dapagliflozin and the effect of dapagliflozin on glimepiride in healthy volunteers. In addition, the safety and tolerability of dapagliflozin with be assessed alone and while taking glimepiride | Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects | [
{
"description": "Tablets, Oral, 20 mg, once daily, single dose",
"name": "Dapagliflozin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Tablets, Oral, 4 mg, once daily, single dose",
"name": "Glimepiride",
"normalized_type": "3d1aa88261d6... | [
{
"design_group_title": "Arm 1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Tablets, Oral, 20 mg, once daily, single dose",
"intervention_name": "Dapagliflozin",
... | [
"Diabetes Mellitus, Type 2"
] | [
"AstraZeneca PLC"
] | [
"Bristol Myers Squibb Co."
] | [
[
{
"name": "达格列净",
"lang": "CN"
},
{
"name": "Dapagliflozin",
"lang": "EN"
},
{
"name": "ダパグリフロジンプロピレングリコール水和物",
"lang": "JP"
}
]
] | null |
NCT07424222 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB00544306"
]
},
{
"id_field": "acronym",
"id_value": [
"RISE"
]
},
{
"id_field": "secondary_id",
"id_value": [
"IRB00544306"
]
}
] | https://clinicaltrials.gov/study/NCT07424222 | Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE) | This is a pilot study to gather information about safety and efficacy of using ruxolitinib (RUX) to treat Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) occurring after CAR-T therapy. In addition, correlative studies will be done to 1) estimate the optimal duration of RUX ther... | Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE) | [
{
"description": "In this study, Ruxolitinib will be supplied as 5 mg tablets which will be administered orally twice daily (BID) as an open-label, investigational product.<br/>Ruxolitinib dosing based on platelet numbers:<br/>* 5 mg twice a day if platelets are under 30,000/µL,<br/>* 10 mg twice a day if plate... | [
{
"design_group_description": "Patients will receive ruxolitinib at a dose of 5 mg twice a day if platelets are under 30,000/µL, ruxolitinib 10 mg twice a day if platelets are ≥30,000/µL but under 50,000/µL, or ruxolitinib 15 mg twice a day if platelets are ≥50,000/µL at the start of treatment.<br/>If a favorab... | [
"Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)"
] | [
"The Sidney Kimmel Comprehensive Cancer Center"
] | [
"Incyte Corp."
] | [
[
{
"name": "磷酸芦可替尼",
"lang": "CN"
},
{
"name": "Ruxolitinib Phosphate",
"lang": "EN"
},
{
"name": "ルキソリチニブリン酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "RISE"
}
] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.